WO1995011924A1 - Non-antigenic branched polymer conjugates - Google Patents

Non-antigenic branched polymer conjugates Download PDF

Info

Publication number
WO1995011924A1
WO1995011924A1 PCT/US1994/012237 US9412237W WO9511924A1 WO 1995011924 A1 WO1995011924 A1 WO 1995011924A1 US 9412237 W US9412237 W US 9412237W WO 9511924 A1 WO9511924 A1 WO 9511924A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
poly
conjugate
branched
antigenic
Prior art date
Application number
PCT/US1994/012237
Other languages
French (fr)
Inventor
Richard B. Greenwald
Anthony Martinez
Original Assignee
Enzon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22503911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1995011924(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzon, Inc. filed Critical Enzon, Inc.
Priority to AU80902/94A priority Critical patent/AU8090294A/en
Priority to JP51278595A priority patent/JP3626494B2/en
Priority to DK94932032T priority patent/DK0788515T3/en
Priority to DE69427045T priority patent/DE69427045T2/en
Priority to CA002174325A priority patent/CA2174325C/en
Priority to EP94932032A priority patent/EP0788515B1/en
Publication of WO1995011924A1 publication Critical patent/WO1995011924A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Definitions

  • the present invention relates to branched polymers which are useful in extending the in vivo circulating life of biologically active materials.
  • the invention also relates to conjugates made with the polymers.
  • activation To conjugate poly(alkylene oxides), one of the hydroxyl end-groups is converted into a reactive functional group. This process is frequently referred to as “activation” and the product is called an “activated poly(alkylene oxide) " .
  • Other substantially non-antigenic polymers are similarly “activated” or functionalized.
  • the activated polymers are reacted with a therapeutic agent having nucleophilic functional groups that serve as attachment sites.
  • nucleophilic functional group commonly used as an attachment site is the e-amino groups of lysines.
  • Free carboxylic acid groups suitably activated carbonyl groups, oxidized carbohydrate moieties and mercapto groups have also been used as attachment sites. Insulin and hemoglobin were among the first therapeutic agents conjugated.
  • These relatively large polypeptides contain several free e-amino attachment sites. A sufficient number of polymers could be attached to reduce immunogenicity and increase the circulating life without significant loss of biologic activity.
  • polymer conjugation and/or conjugation involving a therapeutic moiety's active site where groups associated with bioactivity are found often result in loss of activity and thus therapeutic usefulness. This is often the case with lower molecular weight peptides which have few attachment sites not associated with bioactivity. Many non-peptide therapeutics also lack a sufficient number of attachment sites to obtain the benefit of polymer modification.
  • Another alternative suggested is to attach two strands of polymer via a triazine ring to amino groups of a protein. See, for example, Enzyme. 26. 49-53 (1981) and Proc. Soc. Exper. Biol. Med.. 188, 364-9 (1988) .
  • Triazine is a toxic substance which is difficult to reduce to acceptable levels after conjugation.
  • triazine is a planar group and can only be double-polymer substituted. The planar structure rigidly locks the two polymer chains in place. This limits the benefits of polymer conjugation to about the same as that obtained by increasing polymer chain length.
  • non-triazine- based activated polymers would offer substantial benefits to the art. The present invention addresses this need.
  • (A) represents an activating functional group capable of undergoing nucleophilic substitution.
  • (A) can be a group which is capable of bonding with biologically active nucleophiles or moieties capable of doing the same.
  • (R) includes a poly(alkylene oxide) PAO such as a poly(ethylene glycol) PEG.
  • umbrella-like branched polymers of the present invention react with biologically active nucleophiles to form conjugates.
  • the point of polymer attachment depends upon the functional group (A) .
  • (A) can be a succinimidyl succinate or carbonate and react with epsilon amino lysines.
  • the branched polymers can also be activated to link with any primary or secondary amino group, mercapto group, carboxylic acid group, reactive carbonyl group or the like found on biologically-active materials. Other groups are apparent to those of ordinary skill in the art.
  • the biologically active materials include proteins, peptides, enzymes, medicinal chemicals or organic moieties whether synthesized or isolated from nature.
  • the methods include contacting a biologically active material containing a nucleophile capable of undergoing a substitution reaction with a branched polymer described above under conditions sufficient to effect attachment while maintaining at least a portion of the biological activity.
  • the present invention also includes methods of treating various maladies and conditions.
  • a mammal in ' need of treatment is administered an effective amount of a conjugate containing a biologically-active material such as a protein, enzyme or organic moiety and a branched polymer of the present invention.
  • the branching of the polymers imparts an umbrella-like three-dimensional protective covering to the materials they are conjugated with. This contrasts with the string-like structure of conventional polymer conjugates.
  • the branching of the polymer chains from a common root allows dynamic, non-planar action in vivo.
  • the branched polymers offer substantial benefits over straight-chained polymers of equivalent molecular weight.
  • a second advantage of the branched polymers is that they provide the benefits associated with attaching several strands of polymers to a bioeffecting material but require substantially fewer conjugation sites.
  • the advantages of the branched polymers are particularly dramatic for therapeutic agents having few available attachment sites. All the desired properties of polymer conjugation are realized and loss of bioactivity is minimized.
  • the activated branched polymers of the present invention are preferably prepared from poly(alkylene oxides) (PAO's) that are water soluble at room temperatures.
  • PAO's poly(alkylene oxides)
  • alpha-substituted polyalkylene oxide derivatives such as methoxypoly (ethylene glycols) (mPEG) or other suitable alkyl substituted PAO derivatives such as those containing mono or bis terminal Cj - C 4 groups.
  • Straight-chained non- antigenic polymers such as monomethyl PEG homopolymers are preferred.
  • Alternative polyalkylene oxides such as other poly(ethylene glycol) homopolymers, other alkyl- poly(ethylene oxide) block copolymers, and copolymers of block copolymers of poly(alkylene oxides) are also useful.
  • the polymers of the present invention are represented by Formula (I) :
  • (R) includes a water-soluble, substantially non-antigenic polymer
  • (A) represents an activating functional group capable of undergoing nucleophilic substitution.
  • Each (R) can be a water-soluble, substantially non- antigenic polymer chain.
  • the polymer chains are PEG or mPEG, it is preferred that each chain have a molecular weight of between about 200 and about 12,000 daltons and preferably between about 1,000 and about 10,000 daltons. Molecular weights of about 5,000 daltons are most preferred.
  • Alternative polymeric substances include materials such as dextrans, polyvinyl pyrrolidones, polyacrylamides or other similar non-immunogenic polymers. Such polymers are also capable of being functionalized or activated for inclusion in the invention. The foregoing is merely illustrative and not intended to restrict the type of non-antigenic polymers suitable for use herein.
  • (R) is a branched polymer for secondary and tertiary branching from a bioactive material.
  • Bifunctional and hetero- bifunctional active polymer esters can also be used.
  • the polymers of the present invention can also be copolymerized with bifunctional materials such as poly(alkylene glycol) diamines to form interpenetrating polymer networks suitable for use in permeable contact lenses, wound dressings, drug delivery devices and the like.
  • the stearic limitations and water solubility of such branching will be readily recognized by one of ordinary skill in the art.
  • the molecular weight of multiply branched polymers should not exceed 80,000 daltons.
  • Suitable aliphatics include substituted alkyl diamines and triamines, lysine esters and malonic ester derivatives.
  • the linking moieties are preferably non-planar, so that the polymer chains are not rigidly fixed.
  • the linking moiety (L) is also the means for attaching the multiple polymer chains or "branches" to (A) , the moiety through which the polymer attaches to bio-effecting " materials.
  • (L) preferably includes a multiply-functionalized alkyl group containing up to 18, and more preferably between 1-10 carbon atoms.
  • a heteroatom such as nitrogen, oxygen or sulfur may be included within the alkyl chain.
  • the alkyl chain may also be branched at a carbon or nitrogen atom.
  • ⁇ L) is a single nitrogen atom.
  • each (R) is suitably functionalized to undergo nucleophilic substitution and bond with (L) .
  • Such functionalization of polymers is readily apparent to those of ordinary skill in the art.
  • linkages are contemplated between (R) and (L) .
  • Urethane (carbamate) linkages are preferred.
  • the bond can be formed, for example, by reacting an amino group such as 1, 3-diamino-2-propanol with methoxypolyethylene glycol succinimidyl carbonate described in U.S. Patent No. 5,122,614, the disclosure of which is incorporated herein by reference.
  • Amide linkages which can be formed by reacting an amino- terminated non-antigenic polymer such as methoxy ⁇ polyethylene glycol-amine (mPEG amine) with an acyl chloride functional group.
  • linkages between (R) and (L) include ether, amine, urea, and thio and thiol analogs thereof, as well as the thio and thiol analogs of the above-discussed urethane and amide linkages.
  • the linkages are formed by methods well understood by those of ordinary skill in the art. Other suitable linkages and their formation can be determined by reference to the above-cited U.S. Patent No. 4,179,337.
  • (A) can be a moiety selected from:
  • Functional groups capable of reacting with an amino group such as: a) carbonates such as the p-nitrophenyl, or succinimidyl; b) carbonyl imidazole; c) azlactones; d) cyclic imide thiones; or e) isocyanates or isothiocyanates .
  • Functional groups capable of reacting with carboxylic acid groups and reactive carbonyl groups such as: a) primary amines; or 5 b) hydrazine and hydrazide functional groups such as the acyl hydrazides, carbazates, semicarbamates, thiocarbazates, etc.
  • nucleophiles capable of reacting with an electrophilic center.
  • a non-limiting list includes, for example, hydroxyl, amino, carboxyl, thiol groups, active methylene and the like.
  • the moiety (A) can also include a spacer moiety located proximal to the aliphatic linking moiety, (L) .
  • the spacer moiety may be a heteroalkyl, alkoxy, alkyl containing up to 18 carbon atoms or even an additional 5 polymer chain.
  • the spacer moieties can added using standard synthesis techniques. It is to be understood that those moieties selected for (A) can also react with other moieties besides biologically active nucleophiles.
  • the branched polymers are formed using conventional reaction techniques.
  • the linking compound (L) has a number of nucleophilic functional groups which correspond to (n) , (i.e. 2 or 3) .
  • a succinimidyl carbonate active ester of the branched polymer is prepared by contacting a branched polymer subunit (R) n l.. prepared as described above, with p- nitrophenyl chloroformate and thereafter with N- hydroxysuccinimide to form a succinimidyl carbonate.
  • the hydroxy moiety can be reacted with bis-succinimidyl carbonate directly.
  • the polymer subunit C-R ⁇ n L will include hydroxyl, amino, carboxyl and thiol groups, and the like, as well as amino or methylene hydrogens so that it can be attached to (A) .
  • the branched. olymers can also be formed by reacting aliphatic linking compounds substituted with nucleophilic functional groups such as di- or tri-amino, mercapto alcohols or alkyl triols with an activated or functionalized polymer chain such as SC-PEG, PEG-NCO, PEG-NCS, SS-PEG, PEG-acids and acid derivatives.
  • nucleophilic functional groups such as di- or tri-amino, mercapto alcohols or alkyl triols
  • an activated or functionalized polymer chain such as SC-PEG, PEG-NCO, PEG-NCS, SS-PEG, PEG-acids and acid derivatives.
  • synthesis include reacting a polymer functionalized with a nucleophilic moiety such as
  • PEG-alcohol, PEG-amine or PEG-mercaptan with bifunctional molecules such as malonic acid derivatives or glyoxalic acid derivatives.
  • two moles of methoxy-poly(ethylene glycol) amine can be reacted with a substituted or unsubstituted malonyl chloride to form a compound of Formula (II) :
  • Branched polymer (III) can then be activated by first functionalizing with compounds capable of activating the hydroxyl group such as p-nitrophenyl chloroformate to form a reactive p-nitrophenyl carbonate.
  • compounds capable of activating the hydroxyl group such as p-nitrophenyl chloroformate to form a reactive p-nitrophenyl carbonate.
  • the resulting p-nitrophenyl carbonate polymer can be directly reacted with a biologically active nucleophile.
  • the p-nitrophenyl carbonate polymer can also serve as an intermediate. It can be reacted with a large excess of N-hydroxysuccinimide to form a succinimidyl carbonate-activated branched polymer. Other routes to succinimidyl carbonates are available and contemplated for use herein. Alternatively, a p-nitrophenyl carbonate polymer intermediate can be reacted with anhydrous hydrazine to form a carbazate branched polymer.
  • Branched polymer (IV) can be activated by reacting
  • Branched polymers corresponding to Formula (II) , Formula (III) , and the like, can also be extended with a spacer moiety, designated herein as R 2/ between the aliphatic linking moiety and the group capable of undergoing nucleophilic substitution.
  • R 2/ the polymer of Formula (III) with a spacer moiety is represented by Formula (V) : 0
  • Spacer moieties represented by (R 2 ) include but are not limited to:
  • Synthesis of compounds corresponding to (V) include reacting the p-nitrophenyl carbonate or N-succinimidyl carbonate active esters of Formula (III) compounds with reagents such as
  • spacer moieties to a branched polymer
  • R 2 can be joined to linker moieties (L) substituted with groups other than hydroxyl groups.
  • L linker moieties
  • suitable reagents such as substituted isocyanates or isothiocyanates and the like.
  • the terminal groups of the spacer moieties can be similarly functionalized to react with nucleophiles .
  • the activated branched polymers can be purified by conventional methods and reacted with biologically active materials containing nucleophiles capable of bonding with the polymer while maintaining at least some of the activity associated with the material in unmodified form.
  • nucleophiles conjugated with the branched polymers are described as "biologically active" .
  • the term is not limited to physiological or pharmacological activities.
  • nucleophile conjugates such as those containing enzymes, are able to catalyze reactions in organic solvents.
  • inventive polymer conjugates containing proteins such as concanavalin A, immunoglobulin and the like are also useful as laboratory diagnostics.
  • a key feature of all of the conjugates is that at least some portion of the activity associated with the unmodified bio-active material is maintained.
  • the conjugates are biologically active and have numerous therapeutic applications. Mammals in need of treatment which includes a biologically active material can be treated by administering an effective amount of a polymer conjugate containing the desired bioactive material. FoiV' example, m mals in need of enzyme replacement therapy or blood factors can be given branched polymer conjugates containing the desired material.
  • Biologically active nucleophiles of interest of the present invention include, but are not limited to, proteins, peptides, polypeptides, enzymes, organic molecules of natural and synthetic origin such as medicinal chemicals and the like.
  • Enzymes of interest include carbohydrate-specific enzymes, proteolytic enzymes, oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases.
  • examples of enzymes of interest include asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxinases, catalases, chymotrypsin, lipases, uricases, adenosine diphosphatase, tyrosinases and bilirubin oxidase.
  • Carbohydrate-specific enzymes of interest include glucose oxidases, glucodases, galactosidases, glucocerebrosidases, glucouronidases, etc.
  • Proteins, polypeptides and peptides of interest include, but are not limited to, hemoglobin, serum proteins such as blood factors including Factors VII, VIII, and IX; immunoglobulins, cytokines such as interleukins, ⁇ -, ⁇ - and ⁇ -interfer ⁇ ns, colony stimulating factors including granulocyte colony stimulating factors, platelet derived growth factors and phospholipase-activating protein (PLAP) .
  • hemoglobin serum proteins such as blood factors including Factors VII, VIII, and IX
  • immunoglobulins such as interleukins, ⁇ -, ⁇ - and ⁇ -interfer ⁇ ns
  • colony stimulating factors including granulocyte colony stimulating factors, platelet derived growth factors and phospholipase-activating protein (PLAP) .
  • PLAP phospholipase-activating protein
  • proteins of general biological or therapeutic interest include insulin, plant proteins such as lectins and ricins, tumor necrosis factors and related alleles, growth factors such as tissue growth factors, such as TGFCY'S or TGF/3's and epidermal growth factors, hormones, somatomedins, ' erythropoietin, pigmentary hormones, hypothalamic releasing factors, antidiuretic hormones, prolactin, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, tissue plasminogen activator, and the like.
  • Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof.
  • Some proteins such as the interleukins, interferons and colony stimulating factors also exist in non- glycosylated form, usually as a result of using recombinant techniques.
  • the non-glycosylated versions are also among the biologically active nucleophiles of the present invention.
  • the biologically active nucleophiles of the present invention also include any portion of a polypeptide demonstrating in vivo bioactivity. This includes amino acid sequences, antisense moieties and the like, antibody fragments, single chain binding antigens, see, for example U.S. Patent No. 4,946,778, disclosure of which is incorporated herein by reference, binding molecules including fusions of antibodies or fragments, polyclonal antibodies, monoclonal antibodies, catalytic antibodies, nucleotides and oligonucleotides.
  • the proteins or portions thereof can be prepared or isolated by using techniques known to those of ordinary skill in the art such as tissue culture, extraction from animal sources, or by recombinant DNA methodologies.
  • Transgenic sources of the proteins, polypeptides, amino acid sequences and the like are also contemplated. Such materials are obtained form transgenic animals, i.e., mice, pigs, cows, etc., wherein the proteins expressed in milk, blood or tissues.
  • Transgenic insects and baculovirus expression systems are also contemplated as sources.
  • mutant versions of proteins, such as mutant TNF's and/or mutant interferons are also within the scope of the invention.
  • proteins of interest are allergen proteins such as ragweed, J ⁇ itigen E, honeybee venom, mite allergen, and the like.
  • Useful biologically active nucleophiles are not limited to proteins and peptides. Essentially any biologically-active compound is included within the scope of the present invention.
  • the present invention is particularly well-suited for compounds which have few or even a single nucleophilic attachment site for polymer conjugation such as medicinal chemicals whether isolated from nature or synthesized. Chemotherapeutic molecules such as pharmaceutical chemicals i.e.
  • anti-tumor agents cardiovascularagents, anti-neoplasties, anti-infective ⁇ , anti-anxiety agents, gastrointestinal agents, central nervous system-activating agents, analgesics, fertility or contraceptive agents, anti-inflammatory agents, steroidal agents, anti-urecemic agents, cardiovascular agents, vasodilating agents, vasoconstricting agents and the like.
  • One or more of the activated branched polymers can be attached to a biologically active nucleophile by standard chemical reactions.
  • the conjugate is represented by the formula: (VI)
  • the upper limit for (z) will be determined by the number of available nucleophilic attachment sites and the degree of polymer attachment sought by the artisan.
  • the degree of conjugation can be modified by varying the reaction stoichiometry using well-known techniques. More than one polymer conjugated to the nucleophile can be obtained by reacting a stoichiometric excess of the activated polymer with the nucleophile.
  • the biologically active nucleophiles can be reacted with the activated branched polymers in an aqueous reaction medium which can be buffered, depending upon the pH requirements of the nucleophile.
  • the optimum pH for the reaction is generally between about 6.5 and about 8.0 and preferably about 7.4 for proteinaceous/polypeptide materials.
  • Organic/chemotherapeutic moieties can be reacted in non-aqueous systems.
  • the optimum reaction conditions for the nucleophile's stability, reaction efficiency, etc. is within level of ordinary skill in the art.
  • the preferred temperature range is between 4°C and
  • the temperature of the reaction medium cannot exceed the temperature at which the nucleophile may denature or decompose. It is preferred that the nucleophile be reacted with an excess of the activated branched polymer.
  • the conjugate is recovered and purified such as by diafiltration, column chromatography, combinations thereof, or the like.
  • the activated branched non-antigenic polymers of the present invention are a new and useful tool in the conjugation of biologically active materials, especially when they lack a sufficient number of suitable polymer attachment sites.
  • Methoxypoly(ethylene glycol) was obtained from Union Carbide. The solvents were obtained from Aldrich Chemical of Milwaukee, Wisconsin. The methoxy ⁇ poly(ethylene glycol) -N-succinimidyl carbonate (SC-PEG) was prepared as described in U.S. Patent No. 5,122,614, using m-PEG having a molecular weight of about 5,000. Each of the products prepared in Examples 1 - 9 were confirmed structurally by carbon - 13 NMR.
  • This branched polymer was prepared by adding 100 mg (1.1 mmol) of 1, 3-diamino-2-propanol to a solution of 10.0 g (2 mmol) of SC-PEG in 50 mL of methylene chloride. The mixture was stirred for 18 hours at room temperature then filtered. Excess solvent was removed by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 7.1 g of product (70% yield) .
  • Example 1 The compound .of Example 1 was activated with p- nitrophenyl chloroformate.
  • 5.0g (0.5 mmol) of U- PEG was azeotropically dried by refluxing in 75 mL of toluene for 2 hours, resulting in the removal of 25 mL of solvent/water.
  • the reaction mixture was cooled to 30°C, followed by the addition of 120 mg (0.6 mmol) of p- nitrophenyl chloroformate and 50 mg (0.6 mmol) of pyridine.
  • the resulting mixture was stirred for two hours at 45°C, followed by stirring overnight at room temperature.
  • the U-PNP PEG of Example 2 was reacted with N-hydroxysuccinimide to form the succinimidyl carbonate ester of U-PEG.
  • a solution containing 5.0 g (0.5 mmol) of the U-PNP PEG, 0.6 g (5 mmol) of N-hydroxysuccinimide and 0.13 g (1 mmol) of diisopropylethylamine in 40 ml of methylene chloride was refluxed for 18 hours. The solvent was then removed by distillation in vacuo. and the residue was recrystallized from 2-propanol to yield 4.2 g of the succinimidyl carbonate ester (82% yield) .
  • This branched polymer above was prepared by reacting U-PNP PEG (Ex. 2) with ethanolamine followed by p- nitrophenyl chloroformate.
  • a solution containing 5.0 g (0.5 mmol) of U-PNP PEG in 40 mL of methylene chloride was combined with 60 mg (1 mmol) of ethanolamine and stirred overnight at room temperature. Thereafter, the solvent was removed by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 4.3 g of the intermediate (84% yield) shown below:
  • the NU-PEG-OH was prepared by reacting the above intermediate with p-nitrophenyl chloroformate .
  • the intermediate was azeotropically dried by refluxing, 2.0 g (0.2 mmol) in 40 mL toluene for two hours, with the removal of 25 mL of solvent/water.
  • the reaction mixture was cooled, followed by the addition of 0.3 mmol p- nitrophenyl chloroformate and 0.3 mmol pyridine, according to the procedure of Example 2.
  • the resulting mixture was stirred for two hours at 45°C, followed by stirring overnight at room temperature.
  • This branched polymer was prepared by reacting the U-PNP PEG of Example 2 with 2- (2-aminoethoxy) ethanol according to the procedure described in Example 4, (i.e., the amino alcohol was reacted with the p-nitrophenyl carbonate).
  • the recrystallized product yield was 86%.
  • Example 5 The compound of Example 5 was functionalized with p- nitrophenyl carbonate as in Examples 2 and 4. The recrystallized product yield was 83%.
  • succinimidyl carbonate derivative of compound prepared in Example 5 was prepared according to the process described in Example 3, by reacting N-hydroxysuccinimide with the p-nitrophenyl carbonate derivative of Example 6.
  • the recovered product yield was 84%.
  • the branched polymer depicted above was prepared by reacting U-PNP PEG with lysine ethyl ester.
  • a mixture of 5.0 g (1.0 mmol) of the polymer, 150 mg (0.6 mmol) of lysine dihydrochloride and 140 mg (1.8 mmol) of pyridine was refluxed for 18 hours.
  • the solvent was removed by distillation in vacuo.
  • the residue was recrystallized from 2-propanol to yield 4.5 g (88% yield) of product.
  • EPO erythropoietin
  • US-PEG US-PEG
  • Conjugates of erythropoietin (EPO) with US-PEG were prepared by dialyzing two 3.0 mg EPO samples (human recombinant Chinese Hamster Ovary (CHO) cell culture) into 0.1 M phosphate buffer pH 7.0 solutions using a Centricon-10 (Amicon Corporation, Beverly, MA) .
  • the first EPO solution was combined with 1.954 mg (2-fold molar excess) of the US-PEG while the second EPO solution was combined with 3.908 mg (4-fold molar excess) of the US-PEG.
  • the reaction mixtures were stirred for one hour at room temperature (about 22-25°C) .
  • the excess polymer was removed by centrifugation and the reaction mixtures were dialyzed into 10 mM phosphate buffer, pH 8.0. Unreacted EPO was removed on an ion- exchange column (2-HD column, Sepracor) .
  • Tumor Necrosis Factor was conjugated with the XUS-PEG of Example 7.
  • the TNF was also conjugated with the linear SC PEG, methoxypoly(ethylene glycol) succinimidyl carbonate of U.S. Patent No. 5,122,614. Both conjugates were prepared by reacting a 500 micrograms of TNF, 2.0 mg/mL, with a 25-fold molar excess of the polymer. Each reaction was carried out for 140 minutes on ice.
  • the ED ⁇ o for the branched conjugate was 0.29 ng/mL for the concentration-response curve generated by dilutions of 0.1 micrograms/mL and 0.625 ng/mL for the concentration-response curve generated by dilutions of 15 0.01 micrograms/mL.
  • the ED S0 for the linear succinimidyl carbonate conjugates ranged between 8 and 19 ng/mL.

Abstract

Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life in vivo. Substantially fewer sites on the biologically active material are used as attachment sites. Methods of forming the polymer, conjugating the polymers with biologically active moieties and methods of using the conjugates are also disclosed.

Description

NON-ANTIGENIC BRANCHED POLYMER CONJUGATES BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to branched polymers which are useful in extending the in vivo circulating life of biologically active materials. The invention also relates to conjugates made with the polymers.
Some of the initial concepts of coupling peptides or polypeptides to poly(ethylene glycol) PEG and similar water-soluble poly(alkylene oxides) are disclosed in U.S. Patent No. 4,179,337, the disclosure of which is incorporated herein by reference. Polypeptides modified with these polymers exhibit reduced immunogenicity/antigenicity and circulate in the bloodstream longer than unmodified versions.
To conjugate poly(alkylene oxides), one of the hydroxyl end-groups is converted into a reactive functional group. This process is frequently referred to as "activation" and the product is called an "activated poly(alkylene oxide) " . Other substantially non-antigenic polymers are similarly "activated" or functionalized.
The activated polymers are reacted with a therapeutic agent having nucleophilic functional groups that serve as attachment sites. One nucleophilic functional group commonly used as an attachment site is the e-amino groups of lysines. Free carboxylic acid groups, suitably activated carbonyl groups, oxidized carbohydrate moieties and mercapto groups have also been used as attachment sites. Insulin and hemoglobin were among the first therapeutic agents conjugated. These relatively large polypeptides contain several free e-amino attachment sites. A sufficient number of polymers could be attached to reduce immunogenicity and increase the circulating life without significant loss of biologic activity.
Excessiv , polymer conjugation and/or conjugation involving a therapeutic moiety's active site where groups associated with bioactivity are found, however, often result in loss of activity and thus therapeutic usefulness. This is often the case with lower molecular weight peptides which have few attachment sites not associated with bioactivity. Many non-peptide therapeutics also lack a sufficient number of attachment sites to obtain the benefit of polymer modification.
One suggestion for overcoming the problems discussed above is to use longer, higher molecular weight polymers. These materials, however, are difficult to prepare and expensive to use. Further, they provide little improvement over more readily available polymers.
Another alternative suggested is to attach two strands of polymer via a triazine ring to amino groups of a protein. See, for example, Enzyme. 26. 49-53 (1981) and Proc. Soc. Exper. Biol. Med.. 188, 364-9 (1988) .
Research in this area has continued. Triazine is a toxic substance which is difficult to reduce to acceptable levels after conjugation. In addition, triazine is a planar group and can only be double-polymer substituted. The planar structure rigidly locks the two polymer chains in place. This limits the benefits of polymer conjugation to about the same as that obtained by increasing polymer chain length. Thus, non-triazine- based activated polymers would offer substantial benefits to the art. The present invention addresses this need.
SUMMARY OF THE INVENTION
In one aspect of the invention, there are provided branched, substantially non-antigenic polymers corresponding to the formula:
Figure imgf000005_0001
wherein (R) includes a water-soluble non-antigenic polymer; (n) = 2 or 3; ( jis an aliphatic linking moiety covalently linked to each (R) ,• and
(A) represents an activating functional group capable of undergoing nucleophilic substitution. For example, (A) can be a group which is capable of bonding with biologically active nucleophiles or moieties capable of doing the same.
In particularly preferred aspects of the invention, (R) includes a poly(alkylene oxide) PAO such as a poly(ethylene glycol) PEG.
These umbrella-like branched polymers of the present invention (U-PAO's or U-PEG's) react with biologically active nucleophiles to form conjugates. The point of polymer attachment depends upon the functional group (A) . For example, (A) can be a succinimidyl succinate or carbonate and react with epsilon amino lysines. The branched polymers can also be activated to link with any primary or secondary amino group, mercapto group, carboxylic acid group, reactive carbonyl group or the like found on biologically-active materials. Other groups are apparent to those of ordinary skill in the art.
Other aspects of the invention include conjugates containing biologically-active materials and one or more of the branched polymers described above as well as methods of their preparation. The biologically active materials include proteins, peptides, enzymes, medicinal chemicals or organic moieties whether synthesized or isolated from nature. The methods include contacting a biologically active material containing a nucleophile capable of undergoing a substitution reaction with a branched polymer described above under conditions sufficient to effect attachment while maintaining at least a portion of the biological activity.
The present invention also includes methods of treating various maladies and conditions. In this aspect, a mammal in'need of treatment is administered an effective amount of a conjugate containing a biologically-active material such as a protein, enzyme or organic moiety and a branched polymer of the present invention.
One of the chief advantages of the present invention is that the branching of the polymers imparts an umbrella-like three-dimensional protective covering to the materials they are conjugated with. This contrasts with the string-like structure of conventional polymer conjugates. Moreover, the branching of the polymer chains from a common root allows dynamic, non-planar action in vivo. Thus, the branched polymers offer substantial benefits over straight-chained polymers of equivalent molecular weight.
A second advantage of the branched polymers is that they provide the benefits associated with attaching several strands of polymers to a bioeffecting material but require substantially fewer conjugation sites. The advantages of the branched polymers are particularly dramatic for therapeutic agents having few available attachment sites. All the desired properties of polymer conjugation are realized and loss of bioactivity is minimized.
DETAILED DESCRIPTION OF THE INVENTION
1. POLYMER SUBSTITUENTS AND FORMULA I DEFINED
The activated branched polymers of the present invention are preferably prepared from poly(alkylene oxides) (PAO's) that are water soluble at room temperatures. Within this group are alpha-substituted polyalkylene oxide derivatives such as methoxypoly (ethylene glycols) (mPEG) or other suitable alkyl substituted PAO derivatives such as those containing mono or bis terminal Cj - C4 groups. Straight-chained non- antigenic polymers such as monomethyl PEG homopolymers are preferred. Alternative polyalkylene oxides such as other poly(ethylene glycol) homopolymers, other alkyl- poly(ethylene oxide) block copolymers, and copolymers of block copolymers of poly(alkylene oxides) are also useful.
The polymers of the present invention are represented by Formula (I) :
(R) nL-A (I) wherein:
(R) includes a water-soluble, substantially non-antigenic polymer;
(n) = 2 or 3; ( ) is an aliphatic linking moiety covalently linked to each (R) ; and
(A) represents an activating functional group capable of undergoing nucleophilic substitution.
Each (R) can be a water-soluble, substantially non- antigenic polymer chain. When the polymer chains are PEG or mPEG, it is preferred that each chain have a molecular weight of between about 200 and about 12,000 daltons and preferably between about 1,000 and about 10,000 daltons. Molecular weights of about 5,000 daltons are most preferred.
Alternative polymeric substances include materials such as dextrans, polyvinyl pyrrolidones, polyacrylamides or other similar non-immunogenic polymers. Such polymers are also capable of being functionalized or activated for inclusion in the invention. The foregoing is merely illustrative and not intended to restrict the type of non-antigenic polymers suitable for use herein.
In another embodiment of the invention, (R) is a branched polymer for secondary and tertiary branching from a bioactive material. Bifunctional and hetero- bifunctional active polymer esters can also be used. The polymers of the present invention can also be copolymerized with bifunctional materials such as poly(alkylene glycol) diamines to form interpenetrating polymer networks suitable for use in permeable contact lenses, wound dressings, drug delivery devices and the like. The stearic limitations and water solubility of such branching will be readily recognized by one of ordinary skill in the art. Preferably, however, the molecular weight of multiply branched polymers should not exceed 80,000 daltons.
As shown in Formula I, 2 or 3 polymer chains, designated (R) herein, are joined to the aliphatic linking moiety (L) . Suitable aliphatics include substituted alkyl diamines and triamines, lysine esters and malonic ester derivatives. The linking moieties are preferably non-planar, so that the polymer chains are not rigidly fixed. The linking moiety (L) is also the means for attaching the multiple polymer chains or "branches" to (A) , the moiety through which the polymer attaches to bio-effecting" materials.
(L) preferably includes a multiply-functionalized alkyl group containing up to 18, and more preferably between 1-10 carbon atoms. A heteroatom such as nitrogen, oxygen or sulfur may be included within the alkyl chain. The alkyl chain may also be branched at a carbon or nitrogen atom. In another aspect of the invention, {L) is a single nitrogen atom.
(L) and each (R) are preferably joined by a reaction between nucleophilic functional groups on both (R) and
(L) . Each (R) is suitably functionalized to undergo nucleophilic substitution and bond with (L) . Such functionalization of polymers is readily apparent to those of ordinary skill in the art.
A wide variety of linkages are contemplated between (R) and (L) . Urethane (carbamate) linkages are preferred. The bond can be formed, for example, by reacting an amino group such as 1, 3-diamino-2-propanol with methoxypolyethylene glycol succinimidyl carbonate described in U.S. Patent No. 5,122,614, the disclosure of which is incorporated herein by reference. Amide linkages, which can be formed by reacting an amino- terminated non-antigenic polymer such as methoxy¬ polyethylene glycol-amine (mPEG amine) with an acyl chloride functional group.
Examples of other linkages between (R) and (L) include ether, amine, urea, and thio and thiol analogs thereof, as well as the thio and thiol analogs of the above-discussed urethane and amide linkages. The linkages are formed by methods well understood by those of ordinary skill in the art. Other suitable linkages and their formation can be determined by reference to the above-cited U.S. Patent No. 4,179,337.
The moiety (A) of Formula I represents groups that
"activate" the branched polymers of the present invention for conjugation with biologically active materials. (A) can be a moiety selected from:
I. Functional groups capable of reacting with an amino group such as: a) carbonates such as the p-nitrophenyl, or succinimidyl; b) carbonyl imidazole; c) azlactones; d) cyclic imide thiones; or e) isocyanates or isothiocyanates . II. Functional groups capable of reacting with carboxylic acid groups and reactive carbonyl groups such as: a) primary amines; or 5 b) hydrazine and hydrazide functional groups such as the acyl hydrazides, carbazates, semicarbamates, thiocarbazates, etc.
III. Functional groups capable of reacting with θ mercapto or sulfhydryl groups such as phenyl glyoxals; see, for example, U.S. Patent No. 5,093,531, the disclosure of which is hereby incorporated by reference.
5 IV. Other nucleophiles capable of reacting with an electrophilic center. A non-limiting list includes, for example, hydroxyl, amino, carboxyl, thiol groups, active methylene and the like. 0
The moiety (A) can also include a spacer moiety located proximal to the aliphatic linking moiety, (L) . The spacer moiety may be a heteroalkyl, alkoxy, alkyl containing up to 18 carbon atoms or even an additional 5 polymer chain. The spacer moieties can added using standard synthesis techniques. It is to be understood that those moieties selected for (A) can also react with other moieties besides biologically active nucleophiles.
0
2. SYNTHESIS OF .BRANCHED POLYMERS
The branched polymers (generally, U-PAO's or U- PEG's) are formed using conventional reaction techniques. For each polymer chain (R) attached, the linking compound (L) has a number of nucleophilic functional groups which correspond to (n) , (i.e. 2 or 3) . In one aspect, a succinimidyl carbonate active ester of the branched polymer is prepared by contacting a branched polymer subunit (R) nl.. prepared as described above, with p- nitrophenyl chloroformate and thereafter with N- hydroxysuccinimide to form a succinimidyl carbonate. Alternatively, the hydroxy moiety can be reacted with bis-succinimidyl carbonate directly. The polymer subunit C-R^n L will include hydroxyl, amino, carboxyl and thiol groups, and the like, as well as amino or methylene hydrogens so that it can be attached to (A) .
The branched. olymers can also be formed by reacting aliphatic linking compounds substituted with nucleophilic functional groups such as di- or tri-amino, mercapto alcohols or alkyl triols with an activated or functionalized polymer chain such as SC-PEG, PEG-NCO, PEG-NCS, SS-PEG, PEG-acids and acid derivatives. Such methods are preferred because functionalized polymer chains and suitable aliphatic linking groups are either commercially available or readily synthesized.
Other aspects of synthesis include reacting a polymer functionalized with a nucleophilic moiety such as
PEG-alcohol, PEG-amine or PEG-mercaptan with bifunctional molecules such as malonic acid derivatives or glyoxalic acid derivatives. For example, two moles of methoxy-poly(ethylene glycol) amine can be reacted with a substituted or unsubstituted malonyl chloride to form a compound of Formula (II) :
0 II
Figure imgf000013_0001
0
Reaction with strong base converts the methylene linker into an anion that can be further functionalized.
Likewise, two moles of methoxy-poly(ethylene glycol) succinimidyl carbonate may be reacted with a 1,3 diamino 2-propanol to form a compound of Formula (III) :
0
II
Figure imgf000013_0002
II 0
Similarly, two moles of mPEG can be reacted with a triamine such as diethylenetriamine to form a compound having the structure of Formula (IV) :
0
II
Figure imgf000014_0001
II 0 a=l-5
Branched polymer (III) can then be activated by first functionalizing with compounds capable of activating the hydroxyl group such as p-nitrophenyl chloroformate to form a reactive p-nitrophenyl carbonate. The resulting p-nitrophenyl carbonate polymer can be directly reacted with a biologically active nucleophile.
The p-nitrophenyl carbonate polymer can also serve as an intermediate. It can be reacted with a large excess of N-hydroxysuccinimide to form a succinimidyl carbonate-activated branched polymer. Other routes to succinimidyl carbonates are available and contemplated for use herein. Alternatively, a p-nitrophenyl carbonate polymer intermediate can be reacted with anhydrous hydrazine to form a carbazate branched polymer.
Branched polymer (IV) can be activated by reacting
(IV) with a hydroxy acid such as lactic acid to form the hydroxy amide. Thereafter, the hydroxy amide is functionalized in the same manner discussed above for
(III) . As will be readily appreciated, numerous variations and combinations of the reaction between the functionalized polymer chains and aliphatic linking compound can be utilized to form the compounds of the present invention. The foregoing reactions were disclosed to illustrate the present invention.
Branched polymers corresponding to Formula (II) , Formula (III) , and the like, can also be extended with a spacer moiety, designated herein as R2/ between the aliphatic linking moiety and the group capable of undergoing nucleophilic substitution. For example, the polymer of Formula (III) with a spacer moiety is represented by Formula (V) : 0
Figure imgf000015_0001
II 0
Spacer moieties represented by (R2) include but are not limited to:
-CO-NH-(CH2-)mX -CO-NH- (CH2-CH2-0-)mX
-
Figure imgf000015_0002
and the like, where (m) is an integer between 1 and 18 inclusive and (X) = H, OH, NH2, COOH. Depending upon the circumstances, an -H of an -OH group is attached to the end of the spacer moiety to form the terminal hydroxyl group.
Synthesis of compounds corresponding to (V) include reacting the p-nitrophenyl carbonate or N-succinimidyl carbonate active esters of Formula (III) compounds with reagents such as
H2N-(CH2-)mOH, H2N- (CH2-CH2-0-)mH, aminophenols, or
Figure imgf000016_0001
The attachment of spacer moieties to a branched polymer is described with reference to the polymer of Formula (II) for purposes of illustration, not limitation. Similar products would be obtained with any of the branched polymers disclosed by the present invention. For example, spacer moieties (R2) can be joined to linker moieties (L) substituted with groups other than hydroxyl groups. When the hydroxyl group is replaced by an amino group, or when the carbon substituted with hydroxyl groups is replaced by a secondary amine, (L) can be reacted with suitable reagents such as substituted isocyanates or isothiocyanates and the like. Like the aliphatic linking moieties described above, the terminal groups of the spacer moieties can be similarly functionalized to react with nucleophiles .
After synthesis, the activated branched polymers can be purified by conventional methods and reacted with biologically active materials containing nucleophiles capable of bonding with the polymer while maintaining at least some of the activity associated with the material in unmodified form.
3. BIOLOGICALLYACTIVE MATERIALS SUITABLE FOR CONJUGATION
The nucleophiles conjugated with the branched polymers are described as "biologically active" . The term, however, is not limited to physiological or pharmacological activities. For example, some nucleophile conjugates such as those containing enzymes, are able to catalyze reactions in organic solvents. Likewise, some inventive polymer conjugates containing proteins such as concanavalin A, immunoglobulin and the like are also useful as laboratory diagnostics. A key feature of all of the conjugates is that at least some portion of the activity associated with the unmodified bio-active material is maintained.
The conjugates are biologically active and have numerous therapeutic applications. Mammals in need of treatment which includes a biologically active material can be treated by administering an effective amount of a polymer conjugate containing the desired bioactive material. FoiV' example, m mals in need of enzyme replacement therapy or blood factors can be given branched polymer conjugates containing the desired material.
Biologically active nucleophiles of interest of the present invention include, but are not limited to, proteins, peptides, polypeptides, enzymes, organic molecules of natural and synthetic origin such as medicinal chemicals and the like. Enzymes of interest include carbohydrate-specific enzymes, proteolytic enzymes, oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases. Without being limited to particular enzymes, examples of enzymes of interest include asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxinases, catalases, chymotrypsin, lipases, uricases, adenosine diphosphatase, tyrosinases and bilirubin oxidase. Carbohydrate-specific enzymes of interest include glucose oxidases, glucodases, galactosidases, glucocerebrosidases, glucouronidases, etc.
Proteins, polypeptides and peptides of interest include, but are not limited to, hemoglobin, serum proteins such as blood factors including Factors VII, VIII, and IX; immunoglobulins, cytokines such as interleukins, α-, β- and γ-interferσns, colony stimulating factors including granulocyte colony stimulating factors, platelet derived growth factors and phospholipase-activating protein (PLAP) . Other proteins of general biological or therapeutic interest include insulin, plant proteins such as lectins and ricins, tumor necrosis factors and related alleles, growth factors such as tissue growth factors, such as TGFCY'S or TGF/3's and epidermal growth factors, hormones, somatomedins, ' erythropoietin, pigmentary hormones, hypothalamic releasing factors, antidiuretic hormones, prolactin, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, tissue plasminogen activator, and the like. Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof.
Some proteins such as the interleukins, interferons and colony stimulating factors also exist in non- glycosylated form, usually as a result of using recombinant techniques. The non-glycosylated versions are also among the biologically active nucleophiles of the present invention.
The biologically active nucleophiles of the present invention also include any portion of a polypeptide demonstrating in vivo bioactivity. This includes amino acid sequences, antisense moieties and the like, antibody fragments, single chain binding antigens, see, for example U.S. Patent No. 4,946,778, disclosure of which is incorporated herein by reference, binding molecules including fusions of antibodies or fragments, polyclonal antibodies, monoclonal antibodies, catalytic antibodies, nucleotides and oligonucleotides.
The proteins or portions thereof can be prepared or isolated by using techniques known to those of ordinary skill in the art such as tissue culture, extraction from animal sources, or by recombinant DNA methodologies. Transgenic sources of the proteins, polypeptides, amino acid sequences and the like are also contemplated. Such materials are obtained form transgenic animals, i.e., mice, pigs, cows, etc., wherein the proteins expressed in milk, blood or tissues. Transgenic insects and baculovirus expression systems are also contemplated as sources. Moreover, mutant versions of proteins, such as mutant TNF's and/or mutant interferons are also within the scope of the invention.
Other proteins of interest are allergen proteins such as ragweed, Jϋitigen E, honeybee venom, mite allergen, and the like. Useful biologically active nucleophiles are not limited to proteins and peptides. Essentially any biologically-active compound is included within the scope of the present invention. The present invention is particularly well-suited for compounds which have few or even a single nucleophilic attachment site for polymer conjugation such as medicinal chemicals whether isolated from nature or synthesized. Chemotherapeutic molecules such as pharmaceutical chemicals i.e. anti-tumor agents, cardiovascularagents, anti-neoplasties, anti-infectiveε, anti-anxiety agents, gastrointestinal agents, central nervous system-activating agents, analgesics, fertility or contraceptive agents, anti-inflammatory agents, steroidal agents, anti-urecemic agents, cardiovascular agents, vasodilating agents, vasoconstricting agents and the like.
The foregoing is illustrative of the biologically active nucleophiles which are suitable for conjugation with the polymers of the invention. It is to be understood that those biologically active materials not specifically mentioned but having suitable nucleophilic groups are also intended and are within the scope of the present invention.
4. SYNTHESIS OF BIOLOGICALLY ACTIVE CONJUGATES
One or more of the activated branched polymers can be attached to a biologically active nucleophile by standard chemical reactions. The conjugate is represented by the formula: (VI)
[ (R) n -A1] z- (nucleophile)
wherein (R) is a water-soluble substantially non- antigenic polymer; n = 2 or 3; (L) is an aliphatic linking moiety,; (A1) represents a linkage between (L) and the nucleophile and (z) is an integer ≥ 1 representing the number of polymers conjugated to the biologically active nucleophile. The upper limit for (z) will be determined by the number of available nucleophilic attachment sites and the degree of polymer attachment sought by the artisan. The degree of conjugation can be modified by varying the reaction stoichiometry using well-known techniques. More than one polymer conjugated to the nucleophile can be obtained by reacting a stoichiometric excess of the activated polymer with the nucleophile.
The biologically active nucleophiles can be reacted with the activated branched polymers in an aqueous reaction medium which can be buffered, depending upon the pH requirements of the nucleophile. The optimum pH for the reaction is generally between about 6.5 and about 8.0 and preferably about 7.4 for proteinaceous/polypeptide materials. Organic/chemotherapeutic moieties can be reacted in non-aqueous systems. The optimum reaction conditions for the nucleophile's stability, reaction efficiency, etc. is within level of ordinary skill in the art. The preferred temperature range is between 4°C and
37°C. The temperature of the reaction medium cannot exceed the temperature at which the nucleophile may denature or decompose. It is preferred that the nucleophile be reacted with an excess of the activated branched polymer. Following the reaction, the conjugate is recovered and purified such as by diafiltration, column chromatography, combinations thereof, or the like.
It can be readily appreciated that the activated branched non-antigenic polymers of the present invention are a new and useful tool in the conjugation of biologically active materials, especially when they lack a sufficient number of suitable polymer attachment sites.
EXAMPLES
The following non-limiting examples illustrate certain aspects of the invention. All parts and percentages are by weight unless otherwise noted and all temperatures are in degrees Celsius.
MATERIALS
Methoxypoly(ethylene glycol) (m-PEG) was obtained from Union Carbide. The solvents were obtained from Aldrich Chemical of Milwaukee, Wisconsin. The methoxy¬ poly(ethylene glycol) -N-succinimidyl carbonate (SC-PEG) was prepared as described in U.S. Patent No. 5,122,614, using m-PEG having a molecular weight of about 5,000. Each of the products prepared in Examples 1 - 9 were confirmed structurally by carbon - 13 NMR.
EXAMPLE 1 -
Figure imgf000022_0001
This branched polymer was prepared by adding 100 mg (1.1 mmol) of 1, 3-diamino-2-propanol to a solution of 10.0 g (2 mmol) of SC-PEG in 50 mL of methylene chloride. The mixture was stirred for 18 hours at room temperature then filtered. Excess solvent was removed by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 7.1 g of product (70% yield) .
EXAMPLE 2 - U-PNP-PEG
0 II
Figure imgf000023_0001
II 0
The compound .of Example 1 was activated with p- nitrophenyl chloroformate. First, 5.0g (0.5 mmol) of U- PEG was azeotropically dried by refluxing in 75 mL of toluene for 2 hours, resulting in the removal of 25 mL of solvent/water. The reaction mixture was cooled to 30°C, followed by the addition of 120 mg (0.6 mmol) of p- nitrophenyl chloroformate and 50 mg (0.6 mmol) of pyridine. The resulting mixture was stirred for two hours at 45°C, followed by stirring overnight at room temperature.
The reaction mixture was then filtered through
CELITE™, followed by removal of the solvent from the filtrate by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 4.2 g (81% yield) of the product. EXAMPLE 3 - US-PEG
0
Figure imgf000024_0001
II 0
In this example, the U-PNP PEG of Example 2 was reacted with N-hydroxysuccinimide to form the succinimidyl carbonate ester of U-PEG. A solution containing 5.0 g (0.5 mmol) of the U-PNP PEG, 0.6 g (5 mmol) of N-hydroxysuccinimide and 0.13 g (1 mmol) of diisopropylethylamine in 40 ml of methylene chloride was refluxed for 18 hours. The solvent was then removed by distillation in vacuo. and the residue was recrystallized from 2-propanol to yield 4.2 g of the succinimidyl carbonate ester (82% yield) .
EXAMPLE 4 - NU-PNP-PEG
0
Figure imgf000024_0002
0
This branched polymer above was prepared by reacting U-PNP PEG (Ex. 2) with ethanolamine followed by p- nitrophenyl chloroformate. A solution containing 5.0 g (0.5 mmol) of U-PNP PEG in 40 mL of methylene chloride was combined with 60 mg (1 mmol) of ethanolamine and stirred overnight at room temperature. Thereafter, the solvent was removed by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 4.3 g of the intermediate (84% yield) shown below:
0
Figure imgf000025_0001
0
The NU-PEG-OH was prepared by reacting the above intermediate with p-nitrophenyl chloroformate . The intermediate was azeotropically dried by refluxing, 2.0 g (0.2 mmol) in 40 mL toluene for two hours, with the removal of 25 mL of solvent/water. The reaction mixture was cooled, followed by the addition of 0.3 mmol p- nitrophenyl chloroformate and 0.3 mmol pyridine, according to the procedure of Example 2. The resulting mixture was stirred for two hours at 45°C, followed by stirring overnight at room temperature.
The NU-PEG-OH was also recovered by the procedure in Example 2 to yield 1.5 g (71% yield) . EXAMPLE 5 - XU-PEG-OH 0
Figure imgf000026_0001
0
This branched polymer was prepared by reacting the U-PNP PEG of Example 2 with 2- (2-aminoethoxy) ethanol according to the procedure described in Example 4, (i.e., the amino alcohol was reacted with the p-nitrophenyl carbonate). The recrystallized product yield was 86%.
EXAMPLE 6 - XU-PNP--PEG
The compound of Example 5 was functionalized with p- nitrophenyl carbonate as in Examples 2 and 4. The recrystallized product yield was 83%.
EXAMPLE 7 - XUS-PEG
0
Figure imgf000026_0002
0
In this example, the succinimidyl carbonate derivative of compound prepared in Example 5 was prepared according to the process described in Example 3, by reacting N-hydroxysuccinimide with the p-nitrophenyl carbonate derivative of Example 6. The recovered product yield was 84%.
EXAMPLE 8 - U-LYS-PEG
Figure imgf000027_0001
O
The branched polymer depicted above was prepared by reacting U-PNP PEG with lysine ethyl ester. In particular, a mixture of 5.0 g (1.0 mmol) of the polymer, 150 mg (0.6 mmol) of lysine dihydrochloride and 140 mg (1.8 mmol) of pyridine was refluxed for 18 hours. The solvent was removed by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 4.5 g (88% yield) of product.
EXAMPLE 9 - Synthesis of m-PNP-PEG
mPEG-O 0--
Figure imgf000027_0002
A solution of 50g (0.01 moles) of m-PEG-OH (MW=5000) in 500ml of toluene was azeotroped for 2 hrs, while removing 100ml of toluene/water. The reaction mixture was cooled to 30°C, followed by addition of 2.6 g (0.013 moles) of p-nitrophenyl chloroformate and 1.0 ml (0.013 moles) of pyridine. The resulting mixture was stirred for two hours at 45° C, followed by stirring overnight at room temperature. The reaction mixture was then filtered through
CELITE™, followed by removal of the solvent by distillation in vacuo. The residue was recrystallized from 2-propanol to yield 48.2g (93% yield) of the product.
EXAMPLES 10 and 11
Conjugates of erythropoietin (EPO) with US-PEG (Example 3) were prepared by dialyzing two 3.0 mg EPO samples (human recombinant Chinese Hamster Ovary (CHO) cell culture) into 0.1 M phosphate buffer pH 7.0 solutions using a Centricon-10 (Amicon Corporation, Beverly, MA) . The first EPO solution was combined with 1.954 mg (2-fold molar excess) of the US-PEG while the second EPO solution was combined with 3.908 mg (4-fold molar excess) of the US-PEG. The reaction mixtures were stirred for one hour at room temperature (about 22-25°C) . The excess polymer was removed by centrifugation and the reaction mixtures were dialyzed into 10 mM phosphate buffer, pH 8.0. Unreacted EPO was removed on an ion- exchange column (2-HD column, Sepracor) .
SDS-PAGE analysis confirmed that for both reaction mixtures, about two to three of the branched polymers were covalently bound to each protein molecule. The EPO activity of the conjugates was measured by colorometric assay with DA 1-K cells, a murine ly phoblastic cell line dependent on IL-3, GM-CSF and EPO for growth. The cells are grown in IMDM containing 5% FCS and incubated at 37°C in 5% C02 in air. '• The assay time is 72 hours and cell growth is monitored by MTT dye uptake. In the assay, both conjugate samples retained 40-50% of the activity of the unconjugated EPO. EXAMPLES 12 and 13
Tumor Necrosis Factor (TNF) was conjugated with the XUS-PEG of Example 7. As a comparison, the TNF was also conjugated with the linear SC PEG, methoxypoly(ethylene glycol) succinimidyl carbonate of U.S. Patent No. 5,122,614. Both conjugates were prepared by reacting a 500 micrograms of TNF, 2.0 mg/mL, with a 25-fold molar excess of the polymer. Each reaction was carried out for 140 minutes on ice.
10
The EDεo for the branched conjugate was 0.29 ng/mL for the concentration-response curve generated by dilutions of 0.1 micrograms/mL and 0.625 ng/mL for the concentration-response curve generated by dilutions of 15 0.01 micrograms/mL. The EDS0 for unmodified TNF of 0.01-
0.02 ng/mL. The EDS0 for the linear succinimidyl carbonate conjugates, ranged between 8 and 19 ng/mL.
In vitro tumoricidal and toxicity data indicated 20 that the branched conjugate appears to be more cytotoxic than the non-branched conjugate.
While there have been described what are presently believed to be the preferred embodiments of the
25 invention, those skilled in the art will realize that changes and modifications may be made without departing from the sprit of the invention. It is intended to cliam all such changes and modification s. as fall within the true scope of the invention.
"30

Claims

WHAT IS CLAIMED IS
1. A branched substantially non-antigenic polymer comprising the formula:
W„L-A wherein (R) is a water soluble, substantially non-antigenic polymer;
(n) = 2 or 3;
(L) is an aliphatic linking moiety covalently linked to each (R) and
(A) is a functional group capable of bonding with a biologically active nucleophile or a moiety capable of being functionalized to react with said nucleophiles.
2. The polymer of claim 1, wherein at least one (R) is a straight-chained polymer.
3. The polymer of claim 1, wherein at least one (R) is a poly(alkylene oxide) .
4. The polymer of claim 3, wherein said poly(alkylene oxide) is an α-substituted poly(alkylene oxide) .
5. The polymer of claim 3, wherein said poly(alkylene oxide) is selected from the group consisting of poly(ethylene glycol) homopolymers, alkyl- capped poly(ethylene oxides), and copolymers of block copolymers of poly(alkylene oxides) .
6. The polymer of claim 5, wherein said poly(alkylene oxide) has a molecular weight between about 200 and about 20,000.
7. The polymer of claim 6, wherein said poly(alkylene oxide) has a molecular weight between 2,000 and about 10,000.
8. The polymer of claim 7, wherein said poly(ethylene glycol) homopolymer has a molecular weight of about 5,000.
9. The polymer of claim 2, wherein each (R) is a poly(ethylene glycol) homopolymer.
10. The polymer of claim 1, wherein at least one (R) is a branched polymer.
11. The polymer of claim 1, wherein (L) is an aliphatic moiety.
12. The polymer of claim 11, wherein said aliphatic moiety is selected from the group consisting of sunstituted alkyl diamines and triamines, lysine esters, malonic ester derivatives.
13. The activated branched polymer of claim l, wherein (n) is two..
14. The polymer of claim 1, wherein (A) is a moiety selected from the group consisting of hydroxyl, amino, carboxyl, carbonyl, thiol and methylene hydrogen moieties.
15. The polymer of claim 14, wherein (A) is a succinimidyl or a p-nitrophenyl carbonate active ester.
16. The polymer of claim 1, wherein (A) comprises a spacer moiety proximal to said aliphatic linking moiety
(L) .
17. The polymer of claim 16, wherein said spacer moiety comprises an alkyl or cycloalkyl group containing up to 18 carbon atoms or a polymer.
18. The polymer of claim 1, wherein at least one (R) further comprises a functional group capable of covalently bonding with nucleophiles.
19. A method of forming a biologically active conjugate, comprising: contacting a biologically active nucleophile with an activated branched non-antigenic polymer having a structure represented by:
(R) n -A wherein:
(R) is a water-soluble substantially non- antigenic polymer;
(n) = 2 or 3;
(L) is an aliphatic linking moiety covalently linked to each non-antigenic polymer,- and
(A) is a functional group capable of forming a covalent bond with said biologically active nucleophile.
20. A polymer conjugate comprising the formula:
[ (R) n -A1],- (nucleophile) wherein:
(R) is a water-soluble substantially non- antigenic polymer; (n) = 2 or 3; (L) is an aliphatic linking moiety; (A1) represents a covalent linkage between (L) and the biologically active nucleophile; and (z) represents the number of polymers attached to the nucleophile.
21. The conjugate of claim 20, wherein at least one (R) is a poly(alkylene oxide) .
22. The conjugate of claim 21, wherein said poly(alkylene oxide is an a-substituted poly(alkylene oxide) .
23. The conjugate of claim 21, wherein said poly(alkylene oxide) is selected from the group consisting of pol (ethylene glycol) homopolymers, alkyl- capped poly(ethylene oxides), and copolymers of block copolymers of poly(alkylene oxides) .
24. The conjugate of claim 23, wherein said poly(alkylene oxide) has a molecular weight between about 200 and about 20,000.
25. The conjugate of claim 24, wherein said poly(alkylene oxide) has a molecular weight between 2,000 and about 10,000.
26. The conjugate of claim 25, wherein said poly(ethylene glycol) homopolymer has a molecular weight of about 5,000.
27. The conjugate of claim 21, wherein each (R) is a poly(ethylene glycol) homopolymer.
28. The conjugate of claim 20, wherein at least one (R) is a branched polymer.
29. The conjugate of claim 20, wherein (L) is a non-planar moiety.
30. The conjugate of claim 20, wherein said nucleophile is selected from consisting of proteins, peptide and polypeptides.
31. The conjugate of claim 30, wherein said protein is selected from the group consisting of antibodies, monoclonal antibodies, fragments of antibodies and single chain-binding antigens.
32. The conjugate of claim 30, wherein said peptide and polypeptides are selected from the group consisting of biologically active peptides and polypeptides.
33. The conjugate of claim 20, wherein said nucleophile is a member of the group consisting of anti- neoplastics, anti-infectives, anti-anxiety agents, anti- gastrointestinal agents, central nervous system- activating agents, analgesics, fertility, contraceptive agents, anti-inflammatory agents, steroidal agents, anti- urecemic agents, cardiovascular agents, vasodilating agents, vasconstricting agents.
34. The conjugate of claim 33, wherein said antineoplastic agent is selected from the group consisting of taxol, taxanes, taxoid molecules, anthracyclines and methotrexates.
35. A method of treatment comprising administering to a mammal in need thereof a therapeutically effective amount of the branched polymer conjugate of claim 20.
36. A method of preparing a succinimidyl carbonate active ester of a branched non-antigenic polymer comprising the steps of: i) contacting a branched non-antigenic polymer having a structure represented by:
Wn -A wherein (R) independently comprises a water-soluble substantially non-antigenic polymer; (n) = 2 or 3;
(L) is an aliphatic linking moiety covalently linked to each non-antigenic polymer; and
(A) is a functional group capable of forming a covalent bond with a nucleophile; with p-nitrophenyl chloroformate; and ii) reacting the p-nitrophenyl carbonate active ester of step i) with N-hydroxysuccinimide.
37. The method of claim 36, wherein (A) comprises a spacer moiety proximal to said aliphatic linking group
(L) .
38. A method of preparing a succinimidyl carbonate active ester of a branched non-antigenic polymer comprising the steps of: i) contacting a branched non-antigenic polymer having a structure represented by:
(i?;„ -A wherein (R) independently comprises a water-soluble substantially non-antigenic polymer;
(n) = 2 or 3;
(L) is an aliphatic linking moiety covalently linked to each non-antigenic polymer; and
(A) is a functional group capable of forming a covalent bond with a nucleophile with bis-succinimidyl carbonate.
39. The method of claim 38, wherein (A) comprises a spacer moiety proximal to said aliphatic linking group (L) .
PCT/US1994/012237 1993-10-27 1994-10-24 Non-antigenic branched polymer conjugates WO1995011924A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU80902/94A AU8090294A (en) 1993-10-27 1994-10-24 Non-antigenic branched polymer conjugates
JP51278595A JP3626494B2 (en) 1993-10-27 1994-10-24 Non-antigenic branched polymer complex
DK94932032T DK0788515T3 (en) 1993-10-27 1994-10-24 Non-antigenic branched polymer conjugates
DE69427045T DE69427045T2 (en) 1993-10-27 1994-10-24 NON-ANTIQUE BRANCHED POLYMER CONJUGATES
CA002174325A CA2174325C (en) 1993-10-27 1994-10-24 Non-antigenic branched polymer conjugates
EP94932032A EP0788515B1 (en) 1993-10-27 1994-10-24 Non-antigenic branched polymer conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/143,403 US5643575A (en) 1993-10-27 1993-10-27 Non-antigenic branched polymer conjugates
US08/143,403 1993-10-27

Publications (1)

Publication Number Publication Date
WO1995011924A1 true WO1995011924A1 (en) 1995-05-04

Family

ID=22503911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012237 WO1995011924A1 (en) 1993-10-27 1994-10-24 Non-antigenic branched polymer conjugates

Country Status (8)

Country Link
US (1) US5643575A (en)
EP (2) EP0788515B1 (en)
JP (1) JP3626494B2 (en)
AU (1) AU8090294A (en)
CA (1) CA2174325C (en)
DE (2) DE69434046T2 (en)
DK (2) DK0788515T3 (en)
WO (1) WO1995011924A1 (en)

Cited By (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021469A1 (en) * 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
EP0769955A1 (en) * 1994-06-24 1997-05-02 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
WO1998005363A3 (en) * 1996-08-02 1998-05-07 Ortho Pharma Corp Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
EP0932399A1 (en) * 1996-03-12 1999-08-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US5968779A (en) * 1995-05-05 1999-10-19 Hoffmann-La Roche Inc. Recombinant obese (ob) proteins
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
US6025325A (en) * 1995-05-05 2000-02-15 Hoffman-La Roche Inc. Pegylated obese (ob) protein compositions
WO2001019810A1 (en) * 1999-09-10 2001-03-22 Yunnan Hande Bio-Tech Co. Ltd. Water-soluble cephalomannine esters with poly-amino-acid or the salts thereof, pharmaceutical compositions containing them and their use in medicine
WO2001048052A1 (en) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
WO2001074928A1 (en) * 2000-04-04 2001-10-11 Bioartificial Gel Technologies Inc. Process for the preparation of protein-based hydrogels
JP2001519784A (en) * 1997-03-20 2001-10-23 エンゾン,インコーポレーテッド Non-antigenic branched polymer conjugate
US6340742B1 (en) 1999-07-02 2002-01-22 Roche Diagnostics Gmbh Erythropoietin conjugates
WO2002060978A1 (en) * 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
WO2002076173A2 (en) * 2001-03-21 2002-10-03 The University Of Texas System Inhibitors of glycosaminoglycans
KR100396983B1 (en) * 2000-07-29 2003-09-02 이강춘 Highly reactive branched polymer and proteins or peptides conjugated with the polymer
WO2003093346A1 (en) * 2002-05-06 2003-11-13 Universita' Degli Studi Di Trieste Multifunctional polyethylene glycol derivatives: preparation and use
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
WO2005108463A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US7169754B2 (en) 2000-05-15 2007-01-30 Hoffmann-La Roche Inc. Erythropoietin composition
US7201897B2 (en) 1996-05-31 2007-04-10 Hoffmann-La Roche Inc. Interferon conjugates
EP1704878A3 (en) * 1995-12-18 2007-04-25 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
EP1854807A1 (en) * 2005-02-18 2007-11-14 The University of Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7384977B2 (en) 1996-03-12 2008-06-10 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
EP1982732A2 (en) 2000-02-11 2008-10-22 Maxygen Holdings Ltd. Factor VII or VIIA-like molecules
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459429B2 (en) 2003-12-19 2008-12-02 Hoffmann-La Roche Inc. Method of treating disturbances of iron distribution in inflammatory intestinal diseases
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2080771A2 (en) 2001-02-27 2009-07-22 Maxygen Aps New interferon beta-like molecules
EP2133098A1 (en) 2000-01-10 2009-12-16 Maxygen Holdings Ltd G-CSF conjugates
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US7655747B2 (en) * 1996-09-26 2010-02-02 Nektar Therapeutics Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
WO2010024557A3 (en) * 2008-08-25 2010-06-24 Viromed Co., Ltd. Biopolymer conjugates comprising an interleukin-11 analog
EP2205281A1 (en) * 2007-08-16 2010-07-14 Pharmaessentia Corp. Protein-polymer conjugates
EP2213733A2 (en) 2006-05-24 2010-08-04 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
US7872072B2 (en) 2001-11-07 2011-01-18 Nektar Therapeutics Branched polymers and their conjugates
EP2279756A2 (en) 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
EP2284191A2 (en) 2004-12-22 2011-02-16 Ambrx, Inc. Process for the preparation of hGH
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
EP2327724A2 (en) 2004-02-02 2011-06-01 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US8003125B2 (en) 2000-05-19 2011-08-23 Agency For Science, Technology And Research Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US8067031B2 (en) 2004-04-28 2011-11-29 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US8084572B2 (en) 2000-12-18 2011-12-27 Nektar Therapeutics Segmented polymers and their conjugates
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013006706A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
EP2548967A2 (en) 2006-09-21 2013-01-23 The Regents of The University of California Aldehyde tags, uses thereof in site-specific protein modification
US8377466B2 (en) 1995-12-18 2013-02-19 Angiotech Pharmaceuticals (Us), Inc. Adhesive tissue repair patch
CN102985462A (en) * 2010-06-25 2013-03-20 日油株式会社 Branched hetero-polyethylene glycol and intermediate
US8420068B2 (en) 2005-04-12 2013-04-16 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2633866A2 (en) 2003-10-17 2013-09-04 Novo Nordisk A/S Combination therapy
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US9309507B2 (en) 2010-04-30 2016-04-12 Polytherics Limited Conjugated blood coagulation factor VIIa
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US9353218B2 (en) 2004-09-17 2016-05-31 Angiotech Pharmaceuticals, Inc. Kit for multifunctional compounds forming crosslinked biomaterials
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9579390B2 (en) 2012-11-12 2017-02-28 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US10040761B2 (en) 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
WO2019191482A1 (en) 2018-03-30 2019-10-03 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021236526A1 (en) 2020-05-18 2021-11-25 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
WO2021255524A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Families Citing this family (449)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
ATE502664T1 (en) * 1993-07-19 2011-04-15 Angiotech Pharm Inc METHOD OF PRODUCTION OF A STENT WITH ANTI-ANGIOGENIC COMPOSITION
KR100361933B1 (en) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 Chemically defined nonpolymeric bonds form the platform molecule and its conjugate
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
CA2615918C (en) 1997-02-21 2013-11-26 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
ES2281126T3 (en) * 1997-03-17 2007-09-16 Human Genome Sciences, Inc. RECEIVER 5 CONTAINING A DEATH DOMAIN.
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
EP1011714A2 (en) * 1997-09-18 2000-06-28 F. Hoffmann-La Roche Ag Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
AU741166B2 (en) * 1997-12-12 2001-11-22 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
JP4465109B2 (en) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ,インコーポレーテッド Polymer prodrugs of amino and hydroxyl containing bioactive agents
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
KR20050055053A (en) * 1998-06-08 2005-06-10 에프. 호프만-라 로슈 아게 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
DK2316475T3 (en) 1998-08-06 2017-11-20 Mountain View Pharmaceuticals Inc Isolated tetrameric uricase
PL207369B1 (en) 1998-08-06 2010-12-31 Univ Duke Urate oxidase
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
IL142350A0 (en) * 1998-10-16 2002-03-10 Biogen Inc Interferon-beta fusion proteins and pharmaceutical compositions containing the same
SG2008070138A (en) * 1998-10-16 2017-08-30 Biogen Ma Inc Polymer conjugates of interferon beta- 1a and their uses
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
JP4808846B2 (en) * 1999-02-24 2011-11-02 ザ ユーエイビー リサーチ ファンデイション Taxane derivatives for targeted treatment of cancer
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
DK2093245T3 (en) * 1999-08-27 2012-06-04 Angiodevice Internat Gmbh Biocompatible polymer device
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
JP4776843B2 (en) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド Cancer composition and method using immunoconjugate and chemotherapeutic agent
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
ES2529300T3 (en) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Albumin fusion proteins
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc Human tumor necrosis factor delta and epsilon
KR101287395B1 (en) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
CN1460023A (en) * 2000-07-12 2003-12-03 格莱风治疗公司 Polymer-modified bioactive sythetic chemokines, and method for their mfg. and use
US7118872B2 (en) 2000-08-18 2006-10-10 Dyax Corp. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
AU7338801A (en) * 2000-09-08 2002-03-22 Gryphon Sciences "pseudo"-native chemical ligation
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2001296962A1 (en) * 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
ES2320101T3 (en) 2000-10-16 2009-05-19 Chugai Seiyaku Kabushiki Kaisha CONJUGATED ERYTHROPOYETINE WITH MONO-PEG.
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
ATE361089T1 (en) 2001-02-02 2007-05-15 Ortho Mcneil Pharm Inc TREATMENT OF NEUROLOGICAL FUNCTIONAL DISORDERS WITH FRUCTOPYRANOSE SULFAMATES AND ERYTHROPOETIN
DK1362053T3 (en) * 2001-02-20 2008-03-10 Enzon Inc Terminally branched polymeric linkers and polymeric conjugates containing these
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
EP1572874B1 (en) 2001-05-25 2013-09-18 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
ATE376020T1 (en) 2001-08-22 2007-11-15 Bioartificial Gel Technologies Inc METHOD FOR PRODUCING ACTIVATED POLYETHYLENE GLYCOLS
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1499277B1 (en) 2001-09-24 2009-01-07 Imperial Innovations Limited Pyy3-36 for the reduction or prevention of obesity
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BR0214557A (en) * 2001-11-28 2006-06-06 Ortho Mcneil Pharm Inc erythropoietin dosing regimen for the treatment of anemia
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2003078959A2 (en) * 2002-03-11 2003-09-25 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
DE60315145T2 (en) * 2002-03-13 2008-04-30 Beijing Jiankai Technology Co., Ltd. HYDROPHILIC Y-BRANCH POLYMER DERIVATIVE AND METHOD OF MANUFACTURING THEREOF; ABOVE CONNECTED MEDICAL COMPOSITE
AU2003210052A1 (en) * 2002-03-20 2003-09-29 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
ATE518885T1 (en) * 2002-05-28 2011-08-15 Ucb Pharma Sa PEG POSITION ISOMER OF AN ANTIBODY TO TNFALPHA (CDP870)
MXPA04012496A (en) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Pegylated factor vii glycoforms.
CA2491054A1 (en) * 2002-07-03 2004-01-15 Pericor Science, Inc. Compositions of hyaluronic acid and methods of use
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
MXPA05006944A (en) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta.
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CA2511486A1 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
DE602004024041D1 (en) * 2003-03-05 2009-12-24 Halozyme Inc SOLUBLE HYALURONIDASE GLYCOPROTEIN (SHASEGP), METHOD OF ITS PREPARATION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
JP2006523211A (en) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド Branched water-soluble polymers and their composites
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
EP1624847B1 (en) * 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
TR201907313T4 (en) * 2003-05-23 2019-06-21 Nektar Therapeutics PEG derivatives containing two PEG chains.
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
ATE507845T1 (en) 2003-09-05 2011-05-15 Gen Hospital Corp POLYACETAL DRUG CONJUGATES AS A RELEASE SYSTEM
EP1525890A1 (en) * 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
EP1675620B1 (en) * 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
RS54573B1 (en) 2003-10-14 2016-06-30 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP1694347B1 (en) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
ES2560657T3 (en) 2004-01-08 2016-02-22 Ratiopharm Gmbh O-linked glycosylation of G-CSF peptides
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
US6887952B1 (en) * 2004-02-12 2005-05-03 Biosite, Inc. N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
US7351787B2 (en) 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
DK2626368T3 (en) 2004-07-19 2017-02-27 Biocon Ltd INSULIN OLIGOMS CONJUGATES, FORMULATIONS AND APPLICATIONS THEREOF
AU2005327906B2 (en) * 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006020372A2 (en) * 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (en) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク. Synthetic advanced glycosylated protease resistant polypeptide variants, oral formulations and methods using the same
EP1794588A2 (en) * 2004-09-09 2007-06-13 Biosite Incorporated Methods and compositions for measuring canine bnp and uses thereof
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US8790632B2 (en) * 2004-10-07 2014-07-29 Actamax Surgical Materials, Llc Polymer-based tissue-adhesive form medical use
EP1796746B1 (en) 2004-10-07 2011-05-04 E.I. Du Pont De Nemours And Company Polysaccharide-based polymer tissue adhesive for medical use
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
GB2438982A (en) 2004-12-22 2007-12-12 Ambrx Inc Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006078813A2 (en) * 2005-01-21 2006-07-27 Biosite Incorporated Arginine analogs, and methods for their synthesis and use
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
JP2008530307A (en) * 2005-02-10 2008-08-07 エモリー ユニヴァーシティ Polyethylene oxide polymer containing anti-inflammatory glycodendron
US8012488B2 (en) 2005-02-18 2011-09-06 Nof Corporation Polyoxyalkylene derivative
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR20080009111A (en) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. Variant forms of urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1871877A2 (en) 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20090081122A1 (en) * 2005-05-23 2009-03-26 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1926768B1 (en) * 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
KR100735784B1 (en) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7632823B2 (en) 2005-08-18 2009-12-15 Ambrx, Inc. Compositions of tRNA and uses thereof
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8679536B2 (en) * 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
US8679537B2 (en) * 2005-08-24 2014-03-25 Actamaz Surgical Materials, LLC Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP5905184B2 (en) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. Methods and compositions for use in treating patients with autoantibody positive disease
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101400646A (en) * 2005-11-08 2009-04-01 Ambrx公司 Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
NZ568578A (en) * 2005-12-14 2011-10-28 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
JP5528710B2 (en) * 2006-02-28 2014-06-25 オリガシス コーポレイション Polymer conjugate containing acryloyloxyethyl phosphorylcholine and process for producing the same
CA2645844C (en) 2006-03-13 2016-04-26 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101622270B (en) * 2006-04-12 2014-01-01 萨文特医药公司 Method for purification of proteins with cationic surfactant
CN101062407A (en) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
WO2007130453A2 (en) 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2035016A2 (en) * 2006-06-09 2009-03-18 Enzon Pharmaceuticals, Inc. Indenoisoquinoline-releasable polymer conjugates
MX2009000284A (en) * 2006-06-30 2009-01-26 Enzon Pharmaceuticals Inc Recombinant host for producing l-asparaginase ii.
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
EP2073820A4 (en) * 2006-09-15 2014-07-16 Belrose Pharma Inc Targeted polymeric prodrugs containing multifunctional linkers
US8110559B2 (en) * 2006-09-15 2012-02-07 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5457185B2 (en) 2006-10-04 2014-04-02 ノヴォ ノルディスク アー/エス Glycerol-linked PEGylated sugars and glycopeptides
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
CN101168594B (en) * 2006-10-24 2011-07-27 北京键凯科技有限公司 Polyglycol active derivative with oligopeptide as framework, preparation method thereof and conjugate of with pharmaceutical molecule
AR063384A1 (en) 2006-10-25 2009-01-28 Amgen Inc THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
WO2008066787A2 (en) * 2006-11-27 2008-06-05 E. I. Du Pont De Nemours And Company Multi-functional polyalkylene oxides, hydrogels and tissue adhesives
TWI428346B (en) * 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2008079677A2 (en) * 2006-12-20 2008-07-03 Arkema Inc. Polymer encapsulation and/or binding
JP2010514803A (en) * 2006-12-29 2010-05-06 エンゾン ファーマスーティカルズ インコーポレイテッド Use of adenosine deaminase to treat lung disease
TW200838561A (en) * 2007-01-16 2008-10-01 Enzon Pharmaceuticals Inc Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof
EP2129231A4 (en) * 2007-02-01 2015-01-21 Nat Res Council Canada Formulations of lipophilic bioactive molecules
BRPI0809670A8 (en) 2007-04-03 2018-12-18 Biogenerix Ag methods to increase stem cell production, to increase the number of granulocytes in an individual, to prevent, treat and alleviate myelosuppression that results from cancer therapy, to treat a condition in an individual, to treat neutropenia and thrombocytopenia in a mammal, to expand hematopoietic stem cells in culture, to increase hematopoiesis in an individual, to increase the number of hematopoietic progenitor cells in an individual, and to provide stable bone marrow graft, and, oral dosage form.
ES2569940T3 (en) 2007-04-20 2016-05-13 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase
WO2008131163A1 (en) * 2007-04-20 2008-10-30 Enzon Pharmaceuticals, Inc. Enzymatic anticancer therapy
MX2009012609A (en) 2007-05-22 2009-12-07 Amgen Inc Compositions and methods for producing bioactive fusion proteins.
MX2009013259A (en) 2007-06-12 2010-01-25 Novo Nordisk As Improved process for the production of nucleotide sugars.
CA2693616A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009043027A2 (en) * 2007-09-27 2009-04-02 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
JP5868594B2 (en) 2007-10-16 2016-02-24 バイオコン・リミテッドBiocon Limited Orally administrable solid pharmaceutical composition and process thereof
EP2214730B1 (en) * 2007-11-14 2014-09-24 Actamax Surgical Materials LLC Dextran-based polymer tissue adhesive for medical use
EP2214731B1 (en) * 2007-11-14 2014-05-14 Actamax Surgical Materials LLC Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
EP3042922B1 (en) 2008-01-11 2017-07-19 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
DK2257311T3 (en) 2008-02-27 2014-06-30 Novo Nordisk As Conjugated Factor VIII Molecules
TWI395593B (en) 2008-03-06 2013-05-11 Halozyme Inc In vivo temporal control of activatable matrix-degrading enzymes
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
CA2720048A1 (en) 2008-04-16 2009-10-22 Biogen Idec Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
TWI394580B (en) 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
EP2280739B1 (en) * 2008-06-03 2012-07-04 Actamax Surgical Materials LLC A tissue coating for preventing undesired tissue-to-tissue adhesions
EP2307367B1 (en) 2008-07-08 2014-09-24 Board of Regents, The University of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
US8551136B2 (en) 2008-07-17 2013-10-08 Actamax Surgical Materials, Llc High swell, long-lived hydrogel sealant
US20100015231A1 (en) * 2008-07-17 2010-01-21 E.I. Du Pont De Nemours And Company Low swell, long-lived hydrogel sealant
MY156568A (en) 2008-07-31 2016-03-15 Pharmaessentia Corp Peptide-polymer conjugates
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8466327B2 (en) 2008-11-19 2013-06-18 Actamax Surgical Materials, Llc Aldehyde-functionalized polyethers and method of making same
US9044529B2 (en) * 2008-11-19 2015-06-02 Actamax Surgical Materials, Llc Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
RS58728B1 (en) 2008-12-09 2019-06-28 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
US8491880B2 (en) 2008-12-10 2013-07-23 Mersana Therapeutics, Inc. Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates
EP2379115B1 (en) 2008-12-17 2017-10-25 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
US20100160960A1 (en) * 2008-12-19 2010-06-24 E. I. Du Pont De Nemours And Company Hydrogel tissue adhesive having increased degradation time
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
WO2010104883A1 (en) * 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
US8580732B2 (en) * 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
JP2012523289A (en) 2009-04-09 2012-10-04 アクタマックス サージカル マテリアルズ リミテッド ライアビリティ カンパニー Hydrogel tissue adhesive with reduced degradation time
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
WO2010120365A2 (en) * 2009-04-16 2010-10-21 Wu Nian Protein-carrier conjugates
AR077041A1 (en) 2009-06-09 2011-07-27 Prolong Pharmaceuticals Inc HEMOGLOBIN COMPOSITIONS. METHODS
EP2261662B1 (en) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel synthetic blocking reagents
BRPI1010069A2 (en) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "method for preventing infusion reactions during pegylated uricase therapy in patients; and method for diagnosing whether a patient treated with pegylated uricase will develop infusion reactions or develop antibody-mediated pegylated uricase release without measuring anti-peg antibody titers and pegylated anti-uricase "
US8796242B2 (en) 2009-07-02 2014-08-05 Actamax Surgical Materials, Llc Hydrogel tissue adhesive for medical use
US8580951B2 (en) 2009-07-02 2013-11-12 Actamax Surgical Materials, Llc Aldehyde-functionalized polysaccharides
EP2448604B1 (en) 2009-07-02 2016-03-23 Actamax Surgical Materials LLC Hydrogel tissue adhesive for medical use
US8580950B2 (en) 2009-07-02 2013-11-12 Actamax Surgical Materials, Llc Aldehyde-functionalized polysaccharides
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
BR112012008341A2 (en) 2009-09-15 2020-08-25 Kaneka Corporation modified erythropoietin to which water-soluble long chain molecule is added
MX2012003282A (en) 2009-09-17 2012-04-30 Baxter Healthcare Sa Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof.
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
EP2561076A1 (en) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
US9018348B2 (en) 2010-04-27 2015-04-28 Agency For Science, Technology And Research eIF4E binding peptides
US8828181B2 (en) 2010-04-30 2014-09-09 E I Du Pont De Nemours And Company Temperature switchable adhesives comprising a crystallizable oil
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
ES2661089T3 (en) 2010-07-20 2018-03-27 Halozyme Inc. Methods of treatment or prevention of adverse side effects associated with the administration of an anti-hyaluronan agent
US8409703B2 (en) 2010-07-23 2013-04-02 E I Du Pont De Nemours And Company Temperature switchable adhesive assemblies with temperature non-switchable tack
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
CN103619879A (en) 2010-12-01 2014-03-05 奥尔德生物控股有限责任公司 Anti-ngf compositions and use thereof
JP2014510045A (en) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド Hyaluronan degrading enzyme composition and lipid preparation and its use for the treatment of benign prostatic hypertrophy
BR112013021661A2 (en) 2011-03-02 2016-11-22 Novo Nordisk As objectification of tlt-1 coagulation factor on activated platelets
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
HUE055505T2 (en) 2011-05-20 2021-11-29 H Lundbeck As Anti-cgrp compositions and use thereof
CA3048709A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
WO2013183052A1 (en) 2012-06-04 2013-12-12 Prolor Biotech Inc. Pegylated oxm variants
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
CA2839512C (en) 2011-06-17 2018-01-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
WO2013003593A1 (en) 2011-06-28 2013-01-03 Alternative Innovative Technologies Llc Methods of use of hsp70 for increased performance or hsp70 related disorders
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
WO2013056197A1 (en) 2011-10-14 2013-04-18 Alternative Innovative Technologies Llc Degradation resistant hsp70 formulations and uses thereof
WO2013063155A2 (en) 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
RU2685867C2 (en) 2011-12-15 2019-04-23 Алтернатив Инновейтив Текнолоджиз Ллц Hybrid proteins and protein conjugates based on heat shock protein-70 (hsp70) and methods for use thereof (versions)
AU2012362141B2 (en) 2011-12-30 2017-09-21 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
ES2753124T3 (en) 2012-01-12 2020-04-07 Bioverativ Therapeutics Inc Chimeric factor VIII polypeptides and uses thereof
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
BR112014019901A8 (en) 2012-02-15 2018-01-02 Biogen Idec Inc RECOMBINANT FACTOR VIII PROTEINS
EP2820150A1 (en) 2012-03-01 2015-01-07 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
AU2013243873B2 (en) 2012-04-04 2016-08-25 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2013164375A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
GB201210770D0 (en) * 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
CN104661674A (en) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 Factor VIII complex with XTEN and von willebrand factor protein, and uses thereof
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CA2889170C (en) 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (en) 2012-11-02 2022-05-16 Bioverativ Usa Inc ANTI-COMPLEMENT-C1S ANTIBODIES AND USES THEREOF
US8859705B2 (en) 2012-11-19 2014-10-14 Actamax Surgical Materials Llc Hydrogel tissue adhesive having decreased gelation time and decreased degradation time
KR102341581B1 (en) 2012-11-20 2021-12-21 옵코 바이오로직스 리미티드 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2922870B1 (en) 2012-11-21 2019-08-07 The Governors of the University of Alberta Immunomodulatory peptides and methods of use thereof
EP2935311B1 (en) 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US9272075B2 (en) 2013-02-04 2016-03-01 W.L. Gore & Associates, Inc. Coating for substrate
CA2897127C (en) 2013-02-04 2021-06-29 W.L. Gore & Associates, Inc. Coating for substrate
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
ES2927758T3 (en) 2013-03-14 2022-11-10 Alere San Diego Inc 6-Acetylmorphine analogues and procedures for their synthesis and use
JP6586016B2 (en) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー/エス Antibodies capable of specifically binding to two epitopes on tissue factor coagulation inhibitor
WO2014157117A1 (en) 2013-03-27 2014-10-02 日油株式会社 Purification method for polyethylene glycol having a single amino group
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2910271A1 (en) 2013-04-23 2014-10-30 Nizyme, Inc. Aldh2 for treatment of toxicity associated with an aldh2 deficiency
BR112015030356A2 (en) 2013-06-10 2017-12-05 Ipierian Inc methods of treatment of a taupathy
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
TW201534726A (en) 2013-07-03 2015-09-16 Halozyme Inc Thermally stable PH20 hyaluronidase variants and uses thereof
KR102476907B1 (en) 2013-07-03 2022-12-13 하. 룬드벡 아크티에셀스카브 Regulation of glucose metabolism using anti-cgrp antibodies
US20160184474A1 (en) 2013-07-29 2016-06-30 Actamax Surgical Materials, Llc Low swell tissue adhesive and sealant formulations
ES2761587T3 (en) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res New screening method for the treatment of Friedreich's ataxia
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
JP6509867B2 (en) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド Methods of using interleukin-10 to treat diseases and disorders
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
ES2862139T3 (en) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedures for the use of Interleukin 10 for the treatment of diseases and disorders
MX2016006356A (en) 2013-11-27 2016-10-28 Ipierian Inc Methods of treating a tauopathy.
CN106456718A (en) 2014-01-10 2017-02-22 比奥根Ma公司 Factor viii chimeric proteins and uses thereof
CN106573072A (en) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 Methods of lowering serum cholesterol
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
HUE043847T2 (en) 2014-08-28 2019-09-30 Halozyme Inc Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
CN107001440A (en) 2014-09-26 2017-08-01 拜耳制药股份公司 Stabilized adrenomedulin derivative and application thereof
ES2753391T3 (en) 2014-10-14 2020-04-08 Halozyme Inc Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof
KR20170068553A (en) 2014-10-14 2017-06-19 아르모 바이오사이언시스 인코포레이티드 Interleukin-15 compositions and uses thereof
JP6675394B2 (en) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド Use of interleukin-10 for the treatment of diseases and disorders
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
CN107108711B (en) 2014-10-23 2021-11-23 恩格姆生物制药公司 Pharmaceutical compositions comprising peptide variants and methods of use thereof
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
SG11201702798PA (en) 2014-11-06 2017-05-30 Pharmaessentia Corp Dosage regimen for pegylated interferon
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CA2966964A1 (en) 2014-11-19 2016-05-26 Michal Novak Humanized tau antibodies in alzheimer's disease
KR102526631B1 (en) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
EA033445B1 (en) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-beta-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
ES2748692T3 (en) 2014-11-19 2020-03-17 Nzp Uk Ltd 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroid FXR modulators
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016257724B2 (en) 2015-05-01 2021-02-25 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
KR20180020141A (en) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 PEGylated interleukin-10 for cancer treatment
WO2016196211A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2018517697A (en) 2015-05-29 2018-07-05 オプコ バイオロジクス リミテッド PEGylated oxyntomodulin mutant
KR20240025721A (en) 2015-06-15 2024-02-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Methods and compositions for treating age-associated conditions
CN113289009A (en) 2015-06-19 2021-08-24 Opko生物科学有限公司 Long-acting coagulation factor and production method thereof
UA126016C2 (en) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Factor ix fusion proteins and methods of making and using same
WO2017027545A1 (en) 2015-08-12 2017-02-16 Cell Machines, Inc. Methods and compositions related to long half-life coagulation complexes
CN108025040A (en) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin-10
JP7074341B2 (en) 2015-09-02 2022-05-24 イムテップ エス.アー.エス. Anti-LAG-3 antibody
US10449259B2 (en) 2015-10-02 2019-10-22 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
JP6728352B2 (en) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド How to treat disorders related to bile acids
JP7009364B2 (en) 2015-11-09 2022-02-10 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト Compositions and Methods for Treating Homocystinuria
KR20180104106A (en) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. an anti-CD74 antibody conjugate, a composition comprising an anti-CD74 antibody conjugate, and an anti-CD74 antibody conjugate
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CN116790614A (en) 2016-04-04 2023-09-22 比奥贝拉蒂美国公司 Anti-complement factor BB antibodies and uses thereof
TWI770020B (en) 2016-04-15 2022-07-11 丹麥商H朗德貝克公司 Humanized anti-pacap antibodies and uses thereof
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
AU2017267728B2 (en) 2016-05-18 2021-11-04 Alere San Diego, Inc. 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
EP3468610A1 (en) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
MA46568A (en) 2016-10-24 2019-08-28 Novo Nordisk As BIOLOGICAL DOSAGE OF INSULIN FORMULATIONS
CN116143678A (en) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
JP6935059B2 (en) 2017-03-30 2021-09-15 日油株式会社 A method for purifying polyethylene glycol having one carboxyl group
CA3059592A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US20200216563A1 (en) 2017-08-10 2020-07-09 Friedrich Miescher Institute For Biomedical Research Hdac6 and protein aggregation
KR20200051802A (en) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. Anti-folate receptor alpha antibody conjugates and uses thereof
CN111315398A (en) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 Compositions and methods of use of interleukin-10 in combination with an immune checkpoint pathway inhibitor
TW202003551A (en) 2018-03-28 2020-01-16 美商必治妥美雅史谷比公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2019211842A1 (en) 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN112533629A (en) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 Compositions and methods for combined use of IL-10 agents with chimeric antigen receptor cell therapy
CN114903978A (en) 2018-07-03 2022-08-16 百时美施贵宝公司 FGF-21 formulations
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
KR20210110848A (en) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 Modified urokinase type plasminogen activator polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3924369A1 (en) 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3980423A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
US20220259202A1 (en) 2019-06-17 2022-08-18 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
CN114174326A (en) 2019-06-18 2022-03-11 拜耳公司 Long-term stable adrenomedullin analogues and uses thereof
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023510268A (en) 2020-01-08 2023-03-13 ブリストル-マイヤーズ スクイブ カンパニー FGF-21 conjugate formulation
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
KR20230017207A (en) 2020-04-30 2023-02-03 사이로파 비.브이. Anti-CD103 antibody
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
AU2022330343A1 (en) 2021-08-20 2024-02-08 Bayer Aktiengesellschaft Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
CA3229059A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2024006272A1 (en) 2022-06-27 2024-01-04 Sutro Biopharma, Inc. β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024015229A1 (en) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4889916A (en) * 1985-11-19 1989-12-26 The Johns Hopkins University Protein label and drug delivery system
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5183660A (en) * 1990-08-28 1993-02-02 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
JP2514950B2 (en) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
US4846548A (en) * 1987-05-06 1989-07-11 St&E, Inc. Fiber optic which is an inherent chemical sensor
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP2958019B2 (en) * 1988-05-06 1999-10-06 住友製薬株式会社 Polyethylene glycol derivative, modified peptide and method for producing the same
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
HUT64022A (en) * 1989-04-19 1993-11-29 Enzon Inc Process for producing active polyalkileneoxide carbonates for the modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB8918589D0 (en) * 1989-08-15 1989-09-27 Graham Neil B Polymeric compositions
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4889916A (en) * 1985-11-19 1989-12-26 The Johns Hopkins University Protein label and drug delivery system
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5183660A (en) * 1990-08-28 1993-02-02 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADVANCED DRUG DELIVERY REVIEWS, Volume 6, issued 1991, NUCCI et al., "The Therapeutic Value of Poly(ethylene glycol)-Modified Proteins", pages 133-151. *
BIOCHIMICA ET BIOPHYSICA ACTA, Volume 578, issued 1979, SAVOCA et al., "Preparation of a Non-Immunogenic Arginase by the Covalent Attachment of Polyethylene Glycol", pages 47-53. *
ENZYME, Volume 26, issued 1981, NISHIMURA et al., "Improved Modification of Yeast Uricase With Polyethylene Glycol, Accompanied With Nonimmunoreactivity Towards Anti-Uricase Serum and High Enzymic Activity", pages 49-53. *
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, Volume 64, issued 1981, WIE et al., "Suppression of Reaginic Antibodies With Modified Allergens. III. Preparation of Tolerogenic Conjugates of Common Allergens With Monomethoxypolyethylene Glycols of Different Molecular Weights by the Mixed Anhydride Method", pages 84-99. *
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, Volume 94, issued 1991, SEHON A.H., "Suppression of Antibody Responses by Chemically Modified Antigens", pages 11-20. *
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, Volume 188, issued 1988, KIMURA et al., "A New Tactic for the Treatment of Jaundice: An Injectable Polymer-Conjugated Bilirubin Oxidase (42747)", pages 364-369. *
See also references of EP0788515A4 *

Cited By (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0769955A1 (en) * 1994-06-24 1997-05-02 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
EP0769955A4 (en) * 1994-06-24 1997-11-05 Enzon Inc Non-antigenic amine derived polymers and polymer conjugates
US5902588A (en) * 1994-06-24 1999-05-11 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6177087B1 (en) 1994-06-24 2001-01-23 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US7786221B2 (en) 1995-01-10 2010-08-31 Nektar Therapeutics Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US7419600B2 (en) 1995-01-10 2008-09-02 Nektar Therapeutics Al, Corporation Method for purifying a branched water-soluble polymer
US8546493B2 (en) 1995-01-10 2013-10-01 Nektar Therapeutics Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996021469A1 (en) * 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US8354477B2 (en) 1995-01-10 2013-01-15 Nektar Therapeutics Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5968779A (en) * 1995-05-05 1999-10-19 Hoffmann-La Roche Inc. Recombinant obese (ob) proteins
US6025325A (en) * 1995-05-05 2000-02-15 Hoffman-La Roche Inc. Pegylated obese (ob) protein compositions
US8377466B2 (en) 1995-12-18 2013-02-19 Angiotech Pharmaceuticals (Us), Inc. Adhesive tissue repair patch
US8617584B2 (en) 1995-12-18 2013-12-31 Angiodevice International Gmbh Adhesive tissue repair patch and collagen sheets
US7883694B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Method for preventing the formation of adhesions following surgery or injury
EP1704878A3 (en) * 1995-12-18 2007-04-25 AngioDevice International GmbH Crosslinked polymer compositions and methods for their use
US8197802B2 (en) 1995-12-18 2012-06-12 Angiodevice International Gmbh Method for treating or inhibiting the formation of adhesions following surgery or injury
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
EP0932399A1 (en) * 1996-03-12 1999-08-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
EP0932399A4 (en) * 1996-03-12 2002-10-24 Pg Txl Co Lp Water soluble paclitaxel prodrugs
US7384977B2 (en) 1996-03-12 2008-06-10 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
US7201897B2 (en) 1996-05-31 2007-04-10 Hoffmann-La Roche Inc. Interferon conjugates
WO1998005363A3 (en) * 1996-08-02 1998-05-07 Ortho Pharma Corp Polypeptides having a single covalently bound n-terminal water-soluble polymer
EP1731174A3 (en) * 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
US7655747B2 (en) * 1996-09-26 2010-02-02 Nektar Therapeutics Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US8088365B2 (en) 1996-09-26 2012-01-03 Nektar Therapeutics Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US8404222B2 (en) 1996-09-26 2013-03-26 Nektar Therapeutics Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
JP2010174245A (en) * 1997-03-20 2010-08-12 Enzon Inc Non-antigenic branched polymer conjugate
JP2001519784A (en) * 1997-03-20 2001-10-23 エンゾン,インコーポレーテッド Non-antigenic branched polymer conjugate
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
US6340742B1 (en) 1999-07-02 2002-01-22 Roche Diagnostics Gmbh Erythropoietin conjugates
WO2001019810A1 (en) * 1999-09-10 2001-03-22 Yunnan Hande Bio-Tech Co. Ltd. Water-soluble cephalomannine esters with poly-amino-acid or the salts thereof, pharmaceutical compositions containing them and their use in medicine
EP1270642A1 (en) * 1999-12-24 2003-01-02 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
US7691367B2 (en) 1999-12-24 2010-04-06 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
EP1270642A4 (en) * 1999-12-24 2006-01-18 Kyowa Hakko Kogyo Kk Branched polyalkylene glycols
WO2001048052A1 (en) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP2133098A1 (en) 2000-01-10 2009-12-16 Maxygen Holdings Ltd G-CSF conjugates
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
EP1982732A2 (en) 2000-02-11 2008-10-22 Maxygen Holdings Ltd. Factor VII or VIIA-like molecules
WO2001074928A1 (en) * 2000-04-04 2001-10-11 Bioartificial Gel Technologies Inc. Process for the preparation of protein-based hydrogels
US7202208B2 (en) 2000-05-15 2007-04-10 Hoffman-La Roche Inc. Erythropoietin composition
US7169754B2 (en) 2000-05-15 2007-01-30 Hoffmann-La Roche Inc. Erythropoietin composition
US8003125B2 (en) 2000-05-19 2011-08-23 Agency For Science, Technology And Research Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
KR100396983B1 (en) * 2000-07-29 2003-09-02 이강춘 Highly reactive branched polymer and proteins or peptides conjugated with the polymer
US8084572B2 (en) 2000-12-18 2011-12-27 Nektar Therapeutics Segmented polymers and their conjugates
US8383380B2 (en) 2000-12-18 2013-02-26 Nektar Therapeutics Segmented polymers and their conjugates
WO2002060978A1 (en) * 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
US7547765B2 (en) 2001-01-30 2009-06-16 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
US7291713B2 (en) 2001-01-30 2007-11-06 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP2080771A2 (en) 2001-02-27 2009-07-22 Maxygen Aps New interferon beta-like molecules
WO2002076173A3 (en) * 2001-03-21 2004-04-08 Univ Texas Inhibitors of glycosaminoglycans
WO2002076173A2 (en) * 2001-03-21 2002-10-03 The University Of Texas System Inhibitors of glycosaminoglycans
US8440816B2 (en) 2001-11-07 2013-05-14 Nektar Therapeutics Branched polymers
US8273833B2 (en) 2001-11-07 2012-09-25 Nektar Therapeutics Branched Polymers
US7872072B2 (en) 2001-11-07 2011-01-18 Nektar Therapeutics Branched polymers and their conjugates
US8809453B2 (en) 2001-11-07 2014-08-19 Nektar Therapeutics Branched polymers
US9187569B2 (en) 2001-11-07 2015-11-17 Nektar Therapeutics Branched polymers
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
WO2003093346A1 (en) * 2002-05-06 2003-11-13 Universita' Degli Studi Di Trieste Multifunctional polyethylene glycol derivatives: preparation and use
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US8034900B2 (en) 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
EP2641611A2 (en) 2003-10-17 2013-09-25 Novo Nordisk A/S Combination therapy
EP2633866A2 (en) 2003-10-17 2013-09-04 Novo Nordisk A/S Combination therapy
US7459429B2 (en) 2003-12-19 2008-12-02 Hoffmann-La Roche Inc. Method of treating disturbances of iron distribution in inflammatory intestinal diseases
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EP2327724A2 (en) 2004-02-02 2011-06-01 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US8067031B2 (en) 2004-04-28 2011-11-29 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US8460708B2 (en) 2004-04-28 2013-06-11 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US8481073B2 (en) 2004-04-28 2013-07-09 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
WO2005108463A3 (en) * 2004-05-03 2006-03-30 Nektar Therapeutics Al Corp Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2005108463A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
US9308273B2 (en) 2004-05-03 2016-04-12 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US9353218B2 (en) 2004-09-17 2016-05-31 Angiotech Pharmaceuticals, Inc. Kit for multifunctional compounds forming crosslinked biomaterials
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US7939496B2 (en) * 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2284191A2 (en) 2004-12-22 2011-02-16 Ambrx, Inc. Process for the preparation of hGH
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
EP1854807A4 (en) * 2005-02-18 2009-04-01 Univ Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
NO344209B1 (en) * 2005-02-18 2019-10-14 Nof Corp Lipid membrane structure containing a polyoxyalkylene chain containing lipid derivative and a polyoxyalkylene chain containing lipid derivative
EP1854807A1 (en) * 2005-02-18 2007-11-14 The University of Tokushima Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
EP2279756A2 (en) 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
EP2314320A2 (en) 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
US8420068B2 (en) 2005-04-12 2013-04-16 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
US8636994B2 (en) 2005-04-12 2014-01-28 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP2360170A2 (en) 2005-06-17 2011-08-24 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
EP2213733A2 (en) 2006-05-24 2010-08-04 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
EP2548967A2 (en) 2006-09-21 2013-01-23 The Regents of The University of California Aldehyde tags, uses thereof in site-specific protein modification
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2205281A1 (en) * 2007-08-16 2010-07-14 Pharmaessentia Corp. Protein-polymer conjugates
EP4129343A1 (en) * 2007-08-16 2023-02-08 PharmaEssentia Corp. Protein-polymer conjugates
EP2205281A4 (en) * 2007-08-16 2014-10-08 Pharmaessentia Corp Protein-polymer conjugates
WO2009067636A2 (en) 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3225248A1 (en) 2008-07-23 2017-10-04 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010024557A3 (en) * 2008-08-25 2010-06-24 Viromed Co., Ltd. Biopolymer conjugates comprising an interleukin-11 analog
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9644014B2 (en) 2008-09-26 2017-05-09 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9156899B2 (en) 2008-09-26 2015-10-13 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP3216800A1 (en) 2008-09-26 2017-09-13 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US8569233B2 (en) 2008-09-26 2013-10-29 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
US9309507B2 (en) 2010-04-30 2016-04-12 Polytherics Limited Conjugated blood coagulation factor VIIa
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US10040761B2 (en) 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
CN102985462A (en) * 2010-06-25 2013-03-20 日油株式会社 Branched hetero-polyethylene glycol and intermediate
US10494340B2 (en) 2010-06-25 2019-12-03 Nof Corporation Branched hetero polyethylene glycol and intermediate
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
WO2012024452A2 (en) 2010-08-17 2012-02-23 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP4302783A2 (en) 2010-08-17 2024-01-10 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US9382305B2 (en) 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013004607A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP3088005A1 (en) 2011-07-05 2016-11-02 biOasis Technologies Inc P97-antibody conjugates
WO2013006706A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
EP3584255A1 (en) 2012-08-31 2019-12-25 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
US9579390B2 (en) 2012-11-12 2017-02-28 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US9605078B2 (en) 2012-11-16 2017-03-28 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US11426465B2 (en) 2012-11-16 2022-08-30 Redwiid Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US10888623B2 (en) 2012-11-16 2021-01-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US9833515B2 (en) 2012-11-16 2017-12-05 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US10314919B2 (en) 2012-11-16 2019-06-11 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP3336103A1 (en) 2013-07-10 2018-06-20 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
WO2019191482A1 (en) 2018-03-30 2019-10-03 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
WO2020056066A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021236526A1 (en) 2020-05-18 2021-11-25 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
WO2021255524A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Also Published As

Publication number Publication date
EP1055685B1 (en) 2004-09-29
EP1055685A1 (en) 2000-11-29
US5643575A (en) 1997-07-01
CA2174325A1 (en) 1995-05-04
CA2174325C (en) 2009-05-26
DE69427045D1 (en) 2001-05-10
AU8090294A (en) 1995-05-22
EP0788515B1 (en) 2001-04-04
JP3626494B2 (en) 2005-03-09
JPH09504299A (en) 1997-04-28
DE69427045T2 (en) 2001-10-25
DK0788515T3 (en) 2001-07-16
DE69434046D1 (en) 2004-11-04
EP0788515A1 (en) 1997-08-13
DE69434046T2 (en) 2005-10-06
DK1055685T3 (en) 2005-01-03
EP0788515A4 (en) 1998-07-01

Similar Documents

Publication Publication Date Title
EP0788515B1 (en) Non-antigenic branched polymer conjugates
EP0973819B1 (en) Non-antigenic branched polymer conjugates
EP0769955B1 (en) Non-antigenic amine derived polymers and polymer conjugates
US10456476B2 (en) Method involving 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
EP0824126B1 (en) Preparation of carboxylic acid-containing polyether and biologically active substances derived thereof
KR100653153B1 (en) Sterically hindered derivatives of water soluble polymers
CA2101918A1 (en) Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
EP1988912B1 (en) Methods of preparing activated polymers having alpha nitrogen groups

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CZ FI HU JP KP KR LK MG MN MW NO NZ PL PT RO RU SE SK UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2174325

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994932032

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994932032

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994932032

Country of ref document: EP